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Three Essays on the Opioid Epidemic: Insurance, Treatment and Supply Side Policy 
Mark McInerney, PhD 
University of Connecticut, 2019 
 
Over the past 20 years, the opioid epidemic has driven large increases in poisoning deaths 
throughout the United States. These three essays address unanswered questions within the 
economics and public health literature focused on the opioid epidemic. In the first chapter, I 
examine the relationship between health insurance and opioid related mortality. The Medicaid 
expansions enabled under the Affordable Care Act are used as a natural experiment to generate 
causal estimates of the impact of public insurance expansion on opioid related mortality. In the 
second chapter, I explore the relationship between treatment for opioid use disorder and opioid 
related mortality. Changes in access to treatment are identified using the opening and closing of 
treatment facilities. This strategy enables a comparison of the estimated effect of different types 
of treatment centers based on the services offered and payment type accepted by those facilities. 
In the third chapter, I examine the unintended consequences of policies designed to curb misuse 
of opioids. I test how the introduction of abuse-deterrent prescription opioids has impacted rates 
of viral infection.  
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1 
Chapter 1. Medicaid Expansion and the Opioid Epidemic: How does increasing 
health insurance impact the crisis? 
1. Introduction 
In 2017, about 130 Americans died as a result of an opioid overdose per day (CDC, 
2018). Keith Humphreys, an addiction specialist at Stanford, recently said: “…even if you 
ignored deaths from all other drugs, the opioid epidemic alone is deadlier than the AIDS 
epidemic at its peak” (Ingraham, 2017). As the crisis has unfolded, the Patient Protection and 
Affordable Care Act (ACA) of 2010 began a dramatic reshaping of the American health care 
system. Integral to the law was expansion of health insurance access and more robust 
requirements for coverage of mental health and substance use disorder (SUD) treatments. The 
role of the American medical system in contributing to the opioid epidemic raises important 
questions about individuals who gained health insurance coverage and misuse of opioids. I 
consider two channels through which the expansion of health insurance may impact the opioid 
epidemic: increased access to treatment for opioid use disorder (OUD) and increased access to 
prescription opioids. This study fills a gap in the literature by examining each subcategory of 
opioid related mortality available from the Centers for Disease Control and Prevention (CDC) 
multiple cause of death file. I use a difference-in-differences model to estimate the causal impact 
of public health insurance expansion resulting from the ACA on opioid overdose deaths by using 
variation in Medicaid expansions across states and over time. I find that the Medicaid expansions 
led to decreases in heroin related overdose deaths and increases in methadone related overdose 
deaths. Understanding these effects is of particular importance given recent legislative proposals 
to alter or repeal the ACA and the increasing severity of the opioid epidemic. 
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Because the expansion of Medicaid may have both positive and negative impacts on 
opioid related deaths, I examine each type of opioid mortality individually. Using this 
disaggregation approach, I attempt to disentangle the effects of the Medicaid expansions on 
opioids that Medicaid may fund (opioid analgesics, methadone, etc.) and opioids that Medicaid 
will not fund (heroin, illicit fentanyl, ect.). If the Medicaid expansions impact opioid related 
mortality in both directions, the effects may only be statistically detectable when looking at 
individual categories of cause of death.  
2. Policy Background 
One of the primary goals of the ACA was to increase access to health care for the large 
number of uninsured individuals in the U.S. Toward this goal, the ACA increased the minimum 
income requirement for Medicaid coverage to 138% of the federal poverty level. As a result of a 
2012 Supreme Court decision, the decision to expanded Medicaid was left to states. 36 states and 
Washington D.C. have adopted the Medicaid expansion to date (KFF, 2019).1 The uninsured rate 
among the non-elderly population has decreased from 18.2% in 2010 to 10.5% in 2015 (KFF, 
2017). Medicaid enrollment has increased by 26% nationally (KFF, 2018). Policy uncertainty 
has surrounded the ACA including multiple attempts to repeal the law and the successful repeal 
of the individual mandate in 2017. This policy uncertainty may have undermined potential public 
health benefits of the ACA by discouraging investment in health care infrastructure, 
discouraging potential beneficiaries and causing some insurers to leave the marketplace.  
The ACA required states that expanded Medicaid to offer Alternative Benefit Plans 
(ABP) to the newly eligible expansion population. ABPs were required by law to cover ten 
 
1 In some cases, the expansion of Medicaid has been adopted but not implemented. 
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essential health benefits including treatment for SUDs (Grogan et al., 2016). The ACA does not 
specify which SUD treatment services must be offered. As of October 2017, over 74 million 
individuals were enrolled in Medicaid (Centers for Medicare & Medicaid Services, 2017). 
Overall, about 12% of adult Medicaid beneficiaries have a SUD (Wachino, 2015). Bachrach et 
al. (2016) write: “The expansion population—largely single adults not traditionally covered 
under Medicaid before the ACA—has a higher prevalence of SUDs than populations previously 
eligible for Medicaid.” It is estimated that 1.6 million individuals with SUDs received health 
benefits as a result of the Medicaid expansions (Grogan et al., 2016).   
Medicaid is the largest source of funding for behavioral health treatment in the U.S. 
(Bachrach et al., 2016). For patients with SUDs, most outcomes improve with admission to 
treatment compared to those that don’t seek treatment: decreases in drug use, decreases in 
criminal activity and improvements in social and occupational outcomes (National Institute on 
Drug Abuse, 2012). The American Society of Addiction Medicine (ASAM) guidelines for 
treatment of OUD recommend that psychosocial treatment be used in concurrence with OUD 
medications (Grogan et al., 2016). Such treatments (both impatient and outpatient) and 
medications can be prohibitively costly for the uninsured. 
2.1 Mechanisms  
Of particular concern in this study is the impact of access to health care (though 
insurance) on misuse of opioids. Many current opioid users were first introduced to opioids via 
legal medical channels. Cicero et al. (2014) find that among heroin users entering treatment, 75% 
of users’ first opioid use came in the form of a prescription opioid and by 2010, 94% of users’ 
selected heroin because prescription opioids were becoming too expensive and/or hard to obtain. 
It is increasingly evident that opioids obtained through the American medical system have been 
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misused by recipients and have been diverted from the medical market to the illegal non-medical 
market. Powell et al. (2016) study the introduction of Medicare Part D and find that a 10% 
increase in access to medical opioids led to a 14.1% increase in SUD treatment admissions and a 
7.4% increase in opioid deaths. Expanding Medicaid coverage may increase the supply and 
decrease the cost of prescription opioids (including OUD medications) in a given area. Through 
this channel, increasing health insurance coverage may lead to misuse of opioids (analgesics, 
illicit opioids or OUD medications).  
The FDA has approved three medications to treat OUD: methadone, buprenorphine, and 
naltrexone. These medications are used to relieve opioid withdrawal symptoms and can be used 
safely over long periods of time (months or years). Buprenorphine is the most commonly 
prescribed OUD medication (Wen et al., 2017). Medication Assisted Treatment (MAT) has been 
shown to increase patient survival and patient retention in treatment, decrease opioid misuse and 
improve other outcomes (SAMHSA, 2015). However, FDA approved OUD medications can lead 
to overdose death. There were 66,592 methadone related overdose deaths in the U.S. from 1999-
2016 (CDC Wonder, ICD-10 code T40.3 Methadone, 2018). The rate of methadone related 
overdose death per 100,000 increased by 600% from 1999-2014 (Faul et al., 2017). Methadone 
carries significant risk of overdose as it provides pain relief for about 4-8 hours but stays in the 
body for up to 59 hours (FDA, 2006). Methadone can slow breathing and affect heartbeat. 
Misuse of methadone can occur when patients take higher doses than recommended, take doses 
too frequently, obtain multiple prescriptions or obtain methadone on the black market. 
Methadone may be prescribed and administered under supervision or patients may be given take-
home doses. Methadone misuse and diversion are particularly problematic with respect to take-
home doses (SAMHSA, 2015). The chief medical officer for Medicaid in West Virginia, Dr. 
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James Becker stated: “If you use methadone responsibly and everyone is playing by the rules, 
it’s a safe medication and it’s effective…But if you’re not playing by the rules, it gets out onto 
the street and people die. It has a dual personality” (Vestal, 2015). Misuse of methadone may be 
particularly problematic among Medicaid beneficiaries. Faul et al. (2017) find that in 2014, the 
methadone prescribing rate for Medicaid enrollees was about double that of Commercial Claims 
and Encounters enrollees.  
Recent studies have found significant increases in admissions to specialty treatment and 
prescriptions for medication use to treat SUD in expanding states relative to non-expanding 
states. Meinhofer and Witman (2018) show that aggregate treatment admissions for OUD 
increased by 18% in expanding states. Among Medicaid beneficiaries, opioid related admissions 
increased by 113% in expanding states without crowding out beneficiaries of other insurance 
types (Meinhofer and Witman, 2018). Maclean and Saloner (2019) find that Medicaid coverage 
increased among patients receiving specialty treatment and Medicaid payments for specialty 
treatment increased within expanding states. Further, the volume of prescriptions approved by 
the FDA to treat SUD increased in expanding states (Maclean and Saloner, 2019). Wen et al. 
(2017) find that the expansion of Medicaid in 2014 led to a 70% increase in buprenorphine 
prescriptions covered by Medicaid and a 50% increase in Medicaid spending on buprenorphine. 
Saloner et al. (2018) look across all payers (public, private and cash) and find that buprenorphine 
with naloxone prescriptions increased by about 13% within counties that expanded Medicaid. 
Patient access to MAT is limited in a number of ways. Cost is an important barrier for the 
uninsured population. A full course of buprenorphine maintenance costs about $6,000 per patient 
per year (Wen et al., 2017) while the cost of methadone maintenance is about $4,700 per patient 
per year (National Institute on Drug Abuse, 2012). Medicaid benefits vary across states and may 
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not cover both medications. From 2004-2013, the number of states in which Medicaid benefits 
cover both methadone and buprenorphine increased from 21 states to 32 states (Burns et al., 
2016). Beyond cost, MAT is limited by physician waivers under the Drug Addiction Treatment 
Act of 2000. In order to prescribe FDA approved opioids to treat OUD, physicians must apply 
with the Substance Abuse and Mental Health Services Administration (SAMHSA) for a waiver 
(Jones et al., 2015). Initially, those physicians receiving the waiver can prescribe to up to 30 
patients and up to 100 after one year and with a revised waiver (Jones et al., 2015). Despite these 
patient limits, approximately 44-66% of physicians with the waiver do not prescribe 
buprenorphine at all (Jones et al., 2015).  
There are many other barriers to receiving treatment. These barriers include lack of 
individual desire to stop using, a lack of awareness of treatment options or a lack of awareness of 
the need for treatment (Center for Behavioral Health Statistics and Quality, 2016). Among the 
population of patients aware of the need for treatment, there are other obstacles including strong 
social stigma, waiting lists for admission to treatment, language barriers, transportation barriers 
and others. Only a small percentage of the total population with a SUD receives treatment in a 
given year, about one out of ten (Center for Behavioral Health Statistics and Quality, 2016). An 
estimated 20.2 million adults in the U.S. had a SUD in 2014 (Lipari and Van Horn, 2017).  
2.2 The Opioid Epidemic 
The opioid epidemic is part of a broader public health crisis in the U.S. Case and Deaton 
(2015) show that despite longstanding declining mortality rates, there was an increase in 
mortality rates for US White non-Hispanics ages 45-55 between 1990 and 2010. Increasing 
mortality rates were driven by increases in drug and alcohol poisonings and suicide (Case and 
Deaton, 2015). Pain killers were traditionally prescribed for short-term use, post-surgery pain, 
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and for pain related to life threatening or terminal illnesses. In 1980, a letter to the editor in the 
New England Journal of Medicine noted that patients rarely become addicted to narcotic pain 
killers (Gounder, 2013). A 1986 study published in the Journal of Pain concluded that, for non-
cancer pain, narcotics: “can be safely and effectively prescribed to selected patients with 
relatively little risk of producing the maladaptive behaviors which define opioid abuse” 
(Gounder, 2013).  
Purdue Pharma began manufacturing OxyContin in 1996 and started to encourage 
doctors to prescribe pain killers more frequently. Kolodny et al. (2015) state: “Between 1996 and 
2002, Purdue Pharma funded more than 20,000 pain-related educational programs through direct 
sponsorship or financial grants and launched a multifaceted campaign to encourage long-term 
use of OPRs [Opioid Pain Relievers] for chronic non-cancer pain”. By 2010, OxyContin was the 
15th ranked prescription by retail sales (Alpert et al., 2018). OxyContin became over-prescribed 
and widely available in the US. Some studies have identified OxyContin as one of the causes of 
the opioid epidemic (Kolodny et al., 2015).  
Many policies and interventions intended to curb the opioid epidemic have focused on 
the supply of opioids (Alpert et al., 2018). Recent research has shown that some policies 
focusing on the supply of prescription opioids have had the unintended consequence of leading 
opioid users to substitute across different types of opioids. Persistent misuse of OxyContin led 
Purdue Pharma to reformulate the drug in 2010. OxyContin was typically misused by crushing 
pills and then injecting or inhaling (Alpert et al., 2018). Purdue Pharma introduced a pill that was 
harder to crush and abuse. Evans et al. (2019) find that the rapid increase in heroin related 
overdose deaths began the month after abuse-deterrent OxyContin was introduced. Alpert et al. 
(2018) focus on the geographic variation in the prevalence of OxyContin misuse prior to the 
8 
 
 
introduction of abuse-deterrent OxyContin. The authors find that one additional percentage point 
of OxyContin misuse was associated with 2.5 additional heroin deaths per 100,000 (Alpert et al., 
2018). 
Many states have responded to the opioid epidemic with legislation in different forms. 
Prescription Drug Monitoring Programs (PDMPs) established centralized, electronic databases 
designed to curb overprescribing. PDMPs can regulate over-prescription resulting from 
prescriber behavior and patient behavior. Evidence regarding the effectiveness of PDMPs and 
other policies that sought to curb excessive opioid prescribing has been mixed. Bao et al. (2016) 
find that enacting a PDMP was associated with about a 30% reduction in the prescribing rate of 
Schedule II opioid painkillers. Kilby (2015) shows that PDMPs reduced opioid related overdose 
deaths but were also associated with substitution from prescription opioids to heroin. 
Buchmueller and Carey (2018) find that PDMPs have not affected prescribing rates unless they 
included “must access” clauses, which the majority of PDMPs do not have. In some states, pain 
clinics provided large quantities of opioid analgesics, often with little oversight or medical 
justification (Dowell et al., 2016). 11 states have passed Pain Clinic Laws (PCLs) to establish 
additional regulation and oversight over opioid prescribing. Dowell et al. (2016) find that the 
implementation of PCLs along with PDMPs with mandated provider review decreased opioid 
prescribing rates and opioid related death rates.  
Naloxone (also known by the brand name Narcan) is a substance that can block or 
reverse the effects of opioids in the case of an overdose. Naloxone Access Laws (NALs) make it 
easier for medical professionals to prescribe and distribute Naloxone. Good Samaritan Laws 
(GSLs) remove criminal liability for persons seeking to help a person in danger. Opioid overdose 
deaths are generally not sudden, bystanders able to recognize an overdose can seek medical care 
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and help prevent overdose deaths (Rees et al., 2019). Rees et al. (2019) study the impact of GSLs 
and NALs on opioid related mortality and find that the adoption of NALs was associated with a 
9-11% reduction in opioid-related deaths. The availability of medical marijuana may also impact 
opioid use. For example, in states where medical marijuana is accessible, marijuana may be 
prescribed for chronic pain instead of opioid analgesics. Bachhuber et al. (2014) find that states 
that passed MMLs had about a 25% lower mean annual opioid related death rate.  
3. Data 
The primary outcome variable used in this study is opioid related mortality. These data 
were obtained from the CDC Wide-ranging online data for epidemiologic research (Wonder) 
multiple cause-of-death detailed mortality files. This sample includes data from 1999-2016 at the 
state, year level. Following Rees et al. (2019), I classify all opioid related overdose deaths by 
International Classification of Disease, Tenth Revision (ICD-10) codes as including: T40.0 
(opium), T40.1 (heroin), T40.2 (other opioids), T40.3 (methadone), T40.4 (other synthetic 
narcotics) and T40.6 (other/unspecified narcotics). I consider each of these categories as 
individual outcome variables (excluding opium due to the low number of deaths associated with 
opium). Additionally, I consider ICD-10 code: T50.9 (other and unspecified drugs, medicaments 
and biological substances) which is discussed in more detail in section 6.1. These data include 
underlying cause of death codes: X40-X44 (Unintentional), X60-X64 (Suicide), X85 (Homicide) 
and Y10-Y14 (Undetermined). It should be noted that any one overdose death could involve 
multiple ICD-10 codes (for example, heroin and other opioids were both used by an individual 
that later died). I apply the same classifications to county, year level data (2003-2016). Mortality 
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data with county level identifiers were obtained from The National Association for Public Health 
Statistics and Information Systems (NAPHSIS). 
Second, I consider outcomes from the Centers for Medicare & Medicaid Services State 
Drug Utilization data. I examine data from 2006-2016 containing methadone prescriptions 
reimbursed by Medicaid at the state, quarterly level. I test three outcomes: number of 
prescriptions, Medicaid amount reimbursed and units reimbursed. Medicaid State Drug 
Utilization data separates prescriptions by utilization type (fee for service or managed care) and 
by product code. I aggregate the data to state, quarterly level observations as follows:  
𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛 𝑠,𝑡 =  ∑ 𝑌𝑖,𝑗,𝑠,𝑡
𝑖,𝑗
          (1)   
Where 𝑌𝑖,𝑗,𝑠,𝑡 is the number of prescriptions of product code i, of utilization type j, in state s, in 
quarter t.  
  I control for other changes in state law designed to alleviate the opioid epidemic or that 
may impact outcomes related to the opioid epidemic. These laws include NALs, GSLs, PDMPs 
(including earlier substances monitoring programs), PDMPs with a must access clause, PCLs and 
MMLs (hereafter referred to as other pertinent laws). The effective dates and classification of 
these laws is listed in table A1. Controlling for such changes in state law can eliminate any 
potential confounding impact resulting from policy change unrelated to the Medicaid expansions. 
Data regarding the implementation dates of NALs and GSLs comes from Rees et al. (2019) and 
the Policy Surveillance Program (2018). The effective dates of PDMPs come Kilby (2015) and 
the National Alliance for Model State Drug Laws (2018). Classification and dates of PDMPs 
with a “must access” clause come from Buchmueller and Carey (2018). Implementation dates of 
MMLs come from Baggio et al. (2018). Effective dates of PCLs were derived from Meinhofer 
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and Witman (2018). Medicaid expansion dates come from the Kaiser Family Foundation (KFF) 
and Maclean and Saloner (2019). Unemployment data was obtained from the Bureau of Labor 
Statistics (state and county level). Population and demographic data (state and county level) 
come from the National Center for Health Statistics (NCHS) Bridged-Race Population Estimates. 
Demographic controls include the fraction of the state or county population that is female, white, 
black, ages 0-15, ages 16-35 and ages 36-64. State quarterly level population data were obtained 
from the Bureau of Economic Analysis Personal Income Summary. 
4. Identification Strategy 
 I apply a difference-in-differences (DD) empirical strategy.  Specifically, I estimate the 
following Poisson regression: 
ln (𝜆𝑠,𝑡 ) =  𝛽1 +  𝛽2 𝑀𝑒𝑑𝑖𝑐𝑎𝑖𝑑𝑠,𝑡 +   𝑋𝑠,𝑡 𝛾 +  𝛿𝑡 +  𝜇𝑠 +  + 𝜀𝑠,𝑡          (2)   
The outcome of interest, 𝜆𝑠,𝑡  , is the number of opioid related deaths in state s in year t. 𝑋𝑠,𝑡 is a 
vector of controls including, the natural log of the state population, the state unemployment rate, 
state demographics (age, gender and race) and other pertinent laws. 𝛿𝑡 is the year fixed effect, 
which will capture the aggregate time trends. 𝜇𝑠 is the state fixed effect. 𝛽2 is the coefficient of 
interest, capturing the impact of the Medicaid expansions on opioid related mortality. 
𝑀𝑒𝑑𝑖𝑐𝑎𝑖𝑑𝑠,𝑡 is an indicator variable equal to 1 if the expansion of Medicaid was in effect in state 
s and year t (𝑀𝑒𝑑𝑖𝑐𝑎𝑖𝑑𝑠,𝑡 is a fraction if in place for a portion of that year and equal to 0 
otherwise). Equation 2 is weighted by total population at the state, year level. Standard errors are 
adjusted for clustering at the state level. 
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Of particular concern is the definition of treatment and control in the DD specification. 
Previous Medicaid expansions along with differences among the early expanding states could 
confound the treatment effect (Kaestner et al., 2017). Five states and Washington D.C. expanded 
Medicaid prior to January 1st 2014: CA, CT, D.C., MN, NJ and WA. Within the early expanding 
states, many Medicaid enrollees did not gain insurance; rather, they were shifted from county or 
state level programs resulting from earlier Medicaid expansions (KFF, 2012). CA and CT did 
experience large increases in enrollment following early expansion (KFF, 2012). For this reason, 
CA and CT are the only states among the early expanding states included in my primary 
specification while D.C., MN, NJ and WA are dropped. I consider a number of alternate 
specifications to test the sensitivity of findings to the definition of treatment and control groups 
(see section 5.1 for additional discussion).   
Using survey data from Burns et al. (2016), I estimate a model that takes into account 
differences in Medicaid benefits across states and over time. Using this model, I may more 
accurately identify the treatment effect (expansion of Medicaid) with respect to access to OUD 
medications. This specification is particularly pertinent when estimating models where 
methadone related deaths or methadone prescriptions are the dependent variable and when 
considering the channel of access to MAT for OUD. I estimate the following equation: 
ln(𝜆𝑠,𝑡 ) =  𝛽1 +  𝛽2 𝑀𝑒𝑑𝑖𝑐𝑎𝑖𝑑𝑠,𝑡 ∗ 𝑀𝐴𝑇𝑠,𝑡 + 𝛽3 𝑀𝑒𝑑𝑖𝑐𝑎𝑖𝑑𝑠,𝑡 ∗  𝑂𝑡ℎ𝑒𝑟𝑆𝑡𝑎𝑡𝑒𝑠𝑠,𝑡  +   𝑋𝑠,𝑡 𝛾 +  𝛿𝑡
+  𝜇𝑠 +  𝜀𝑠,𝑡       (3)        
  
Here, 𝑀𝐴𝑇𝑠,𝑡 is an indicator variable equal to 1 if buprenorphine and methadone are covered by 
Medicaid in state s and year t (equal to zero otherwise). 𝑀𝑒𝑑𝑖𝑐𝑎𝑖𝑑𝑠,𝑡 ∗  𝑂𝑡ℎ𝑒𝑟𝑆𝑡𝑎𝑡𝑒𝑠𝑠,𝑡 captures 
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the impact of the expansion of Medicaid in states in which Medicaid benefits do not cover both 
buprenorphine and methadone. 
 The validity of this identification strategy relies on satisfaction of the common trends 
assumption. I test this assumption using event study analysis. The event studies are limited in 
terms of post period data as the majority of expanding states expanded Medicaid in 2014 or later. 
With respect to 2014 expanding states, the data contain 3 total years of event year/post policy 
period data (2014, 2015 and 2016). In specifications including CA and CT, additional post policy 
period data is available. I estimate the following event study model: 
ln(𝜆𝑠,𝑡 ) =  𝛼 + ( ∑ 𝐸𝑆 𝑠,𝑡
3+
𝑡=−5
) 𝛽 +   𝑋𝑠,𝑡 𝛾 +  𝛿𝑡 +  𝜇𝑠 +  + 𝜀𝑠,𝑡       (4)        
Where 𝐸𝑆𝑠,𝑡 is an indicator variable equal to one in treatment state s, in year t in relation to the 
policy change. I begin the event study 5 years prior to the policy change and group all 
observations 3 or more years after the policy change.2 I also estimate event studies in which all 
early and late expanding states are dropped.  
My primary specification uses state, year level data. I present Poisson results as my 
primary specification because the dependent variable of interest is a count. 3 I examine the 
robustness of these results to use of county, year level data and to different distributional 
assumptions about the outcome variable. I convert the outcome variable to a rate of opioid 
related mortality per 100,000 in state s and in year t to estimate OLS models (including the same 
controls except the log population control). The death rate is transformed using the natural log 
 
2 I have also run event studies grouping all pre-treatment years 5 years or more prior to treatment. Event studies 
appear similar in these specifications in terms of pre-trend analysis. 
3 In a few instances, I force Poisson models to converge after 500 iterations if convergence is not achieved. 
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(LN) or inverse hyperbolic sine (IHS) functions.4 Prior to the log transformation, I add 1 to the 
death rate per 100,000 to prevent missing observations.  
5. Results 
Poisson regression results presented in table 2 suggest that the expansion of Medicaid 
resulted in about a 29 percent reduction in heroin related overdose deaths. The magnitude of the 
finding is evident when considering the population weighted mean number of heroin related 
deaths, 202 per state per year. The impact of the Medicaid expansions varies by each 
subcategory of opioid related overdose death. Expansion of Medicaid was associated with a 14 
percent increase in methadone related deaths in the baseline model though the coefficient of 
interest is no longer statistically significant with the inclusion of a full set of controls.5 The 
population weighted mean number of methadone related overdose deaths is about 140 per state 
per year. The coefficient of interest is positive and significant with respect synthetic opioid 
related overdose deaths in the baseline model. However, it may be the case that the rise in 
prevalence of illicit fentanyl has disproportionately impacted the expanding states (see section 
5.3 for additional discussion). Results in table 2 suggest that the expansion of Medicaid would 
lead to a decrease of 58 heroin related deaths and an increase of 19 methadone related deaths in a 
given state, in a given year. Table 3 points to access to MAT through insurance as a crucial 
channel in reducing heroin deaths while also driving increases in methadone related deaths. 
Increases in methadone related overdose deaths may be related to increases in methadone 
treatment for OUD in expanding states, though methadone is also prescribed for chronic pain.  
 
4 IHS transformation is considered given concerns about the LN transformation in the case that the outcome variable 
is zero or close to zero  
5 p-value = 0.188. If the control for MML is dropped, p-value = 0.106 
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5.1 Robustness 
In table 4, I reestimate equation (2) using county, year level data. Similar to the state 
level results, the county level results suggest that the expansion of Medicaid led to a decrease in 
heroin related overdose deaths and an increase in methadone related overdose deaths. Using 
county level data, the increase in methadone related overdose deaths is significant at the 1% level 
with the inclusion of a full set of controls. Next, I test the robustness of results to different 
functional forms including OLS and negative binomial regression results. OLS (table 5) and 
negative binomial (table A7) results show that my findings are relatively robust to different 
distributional assumptions, though the OLS results are less precise. In table 5, again it appears 
that reductions in heroin deaths and increase in methadone deaths were driven by the expansion 
of Medicaid in states in which Medicaid benefits cover both methadone and buprenorphine.    
Next, I test the robustness of these findings to alternate classifications of treatment and 
control. In my primary specification, states that previously expanded Medicaid and did not 
experience significant increases in Medicaid enrollment (D.C., MN, NJ and WA) are dropped 
from the sample. In table A2, I consider 3 alternate methods of coding the Medicaid expansions. 
In row (1), I include all 50 states plus D.C. and define Medicaid expansion dates as shown in 
table 8. In row (2), I include all 50 states (plus D.C.) and assign Medicaid expansion dates based 
on increases in Medicaid enrollment following Meinhofer and Witman (2018). Among the early 
expanding states that expanded Medicaid more than once, Meinhofer and Witman (2018) select 
the date of expansion as the expansion that led to the largest increase in enrollment. In row (3), 
results are shown from my primary specification (D.C., MN, NJ and WA are dropped from the 
sample). In row (4), Oregon and Massachusetts are dropped as both states established health care 
reforms and increased access to health insurance including expansion of public insurance prior to 
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the Medicaid expansions. Results appear robust across these 4 methods of coding treatment and 
control. 
Regression results are weighted by population. Primary results are robust when weighted 
by population (table 2) or unweighted (table A8). As an additional robustness check, I re-
estimate the impact of the expansion of Medicaid on heroin related overdose deaths by dropping 
each treatment state individually (all early expanding states are included in this sample). The 
estimated treatment effect remains relatively stable with the exception of the specification in 
which California is dropped (table A6).6   
5.2 Parallel Trends and Validity of Identification Strategy 
The validity of the estimates presented rests on satisfaction of the parallel trends 
assumption. The parallel trends assumption is examined using visual evidence in the form of 
event study analysis. The event studies do not, in general, exhibit significant pre-trends. Pre-
trends are of particular concern given the politicization of the ACA and the decision to expand 
Medicaid. I present event studies of two types. In figures 2 and 3, I utilize variation in the timing 
of Medicaid expansion including late expanding states and early expanding states (CA and CT 
only). In this specification, the event year varies among the early and late expanding states. 
Figure 2 reveals no visible pre-trends with respect to heroin related overdose deaths. Figure 3 
reveals some visible changes in the pre-policy period with respect to methadone related deaths, 
though a treatment effect appears visible in the post policy period. In the second type of event 
study, all early and late expanding states are dropped from the sample. The treatment group 
includes only states that expanded Medicaid in 2014 and the control group includes all non-
 
6 California represents the largest treatment state in my study both in terms of population and change in insurance 
status with over 2.5 million individuals gaining health insurance by 2017 (KFF, 2017) 
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expanding states. In figures 4 and 5, confidence intervals are centered around or include a zero 
coefficient estimate in the pre-policy period. Following the expansion of Medicaid, heroin deaths 
appear to decrease (figure 4) and methadone deaths appear to increase (figure 5).   
5.3 Illicit Fentanyl 
 In recent years, the increasing prevalence of illicit fentanyl in the U.S. has contributed to 
further increases in opioid mortality. Fentanyl is a synthetic opioid that is approximately 80-100 
stronger than morphine (DEA, 2019). Fentanyl related overdose deaths began to dramatically 
increase around 2014 (see figure 1). The majority of expanding states expanded Medicaid in the 
same year. Unless there is a causal relationship between the expansion of Medicaid and rise in 
illicit fentanyl, the geographic distribution of illicit fentanyl may have differentially impacted the 
expansion states. From 2013-2014, the states with the largest increase in the synthetic opioid 
related death rate (excluding methadone) were Ohio, Massachusetts, Maryland and New 
Hampshire (Gladden et al., 2016). All four of these states expanded Medicaid in 2014. To the 
extent that there is no causal relationship between expansion of Medicaid and the distribution of 
illicit fentanyl, this is a confounding trend which most likely introduces downward bias in the 
estimated public health benefits of the expansion of Medicaid.   
In table 7, I test alternate specifications to account for the rise of illicit fentanyl. In the 
baseline model (row 1) the expansion of Medicaid is associated with a significant increase in 
synthetic opioid related overdose deaths. With the inclusion of controls for other pertinent laws 
(row 2), the coefficient of interest is large in magnitude but no longer statistically significant. In 
row (3), those states that experienced the largest increase in the synthetic opioid related death 
rate (OH, MA, MD and NH) are dropped from the sample. After these four states are excluded, 
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the expansion of Medicaid no longer appears to have explanatory power with respect to synthetic 
opioid deaths (excluding methadone). Following Meinhofer and Witman (2018), I include data 
from the Drug Enforcement Agency National Drug Threat Assessment (NDTA) to control for 
the per capita rate of seizures of illegally manufactured fentanyl. In row (4), inclusion of the 
control for fentanyl seizures removes the explanatory power of the Medicaid expansions with 
respect to synthetic opioid related overdose deaths. States in the Northeastern U.S. have been 
particularly hard hit by illicit fentanyl. In table A4, I consider two separate subsamples excluding 
states in the North East. The primary results presented in the study appear robust to the exclusion 
of these states. Yet in the smaller subsample, again, no relationship appears between the 
expansion of Medicaid and increases in fentanyl related deaths.       
6. Discussion 
Recent studies (Meinhofer and Witman, 2018; Maclean and Saloner, 2019; Saloner et al., 
2018, Wen et al., 2017) have shown increases in prescriptions used to treat OUD and specialty 
treatment admissions in states that expanding Medicaid. Reductions in opioid related overdose 
deaths within the expanding states are most likely explained by increased access to treatment and 
prescriptions used to treat OUD. Maclean and Saloner (2019) do not include methadone in their 
study as methadone is prescribed for uses other than treatment of OUD. Results in table 6 show 
that the expansion of Medicaid was associated with a 20-37 percent increase in methadone 
prescriptions reimbursed by Medicaid, depending on the outcome variable (number of 
prescriptions, amount reimbursed or units reimbursed). The coefficient of interest increases in 
magnitude as estimated by equation (3). In other words, methadone prescriptions increased in 
states that expanded Medicaid in which Medicaid benefits cover methadone. These increases in 
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methadone prescriptions in expanding states are visible in figures 6 and 7. Results in table 6 are 
suggestive of increased utilization of methadone therapy for OUD in expanding states relative to 
non-expanding states. However, methadone is commonly prescribed for chronic pain, 
particularly in cancer patients.  
Results in tables 3 and 6 point to the public health benefits associated with increased 
access to MAT as well as the potential consequences associated with increasing access to 
methadone. Analyzing cause of death by ICD-10 codes enables the separation of methadone 
deaths and other synthetic opioid deaths. However, ICD-10 code T40.4 can include fentanyl, 
propoxyphene, meperidine, or buprenorphine (Kilby, 2015). The methodology used in this study 
does not allow for the separation of deaths caused by fentanyl or buprenorphine. In general, 
buprenorphine is considered to be a safe medication. There may be some consequences 
associated with increased access to buprenorphine. The Tennessee Department of Health recently 
found that some deaths were associated with misuse of buprenorphine and use of buprenorphine 
in concurrence with other prescription or illicit drugs (Tennessee Department of Health, 2018).  
6.1 Measurement Error and Polysubstance Use 
 A major obstacle to the disaggregation approach used in this study is the prevalence of 
polysubstance use or the use of multiple substances by a single user. It is quite common for those 
struggling with OUD to use opioids of different types in concurrence or to use opioids in 
concurrence with other prescription drugs, other illicit drugs and/or alcohol. Polysubstance use 
can increase the risk of overdose. For example, use of benzodiazepines is known to increase the 
risk of overdose death when used with opioids (Mattson et al., 2018). In an 11-state analysis 
taking place from July 2016-June 2017, benzodiazepines were found present in approximately 
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half of deaths categorized as prescription opioid–only deaths (Mattson et al., 2018). 
Polysubstance use is a strong predictor of misuse of prescription opioids (Morley et al., 2017)  
Increased access to MAT could increase the likelihood that methadone, buprenorphine or 
naltrexone are present at the time of an opioid overdose. This may be more pervasive in 
expanding states than non-expanding states. I investigate this issue further in table A3 by re-
coding methadone related deaths in a number of different ways. The county level multiple cause-
of-death data contain a maximum of 20 different conditions. I collect the data and recode 
methadone deaths by excluding each other type of opioid related condition in the data. Across 7 
methods of coding, the Medicaid expansions are still associated with a statistically significant 
increase in methadone related deaths. Table A3 suggests that the increase in methadone deaths in 
expanding states was not driven by the presence of methadone in opioid overdose cases 
involving other opioids.  
In addition to polysubstance use, measurement error presents an obstacle in this study as 
misidentification of cause of death is common. ICD-10 code T50.9 classifies poisoning by 
unspecified drugs, medicaments and biologicals which does not identify any specific drug. From 
1999-2012, 25% of drug poisoning deaths were identified with no specific drug mentioned 
(Ruhm, 2016). Svetla et al. (2015) write: "If they [coroners and medical examiners] instead write 
“opioid” alone, the death will be coded to T40.6, “other and unspecified narcotics,” because the 
information is not sufficient to assign a specific ICD-10 code (i.e., T40.2, “other opioids”; T40.3, 
“methadone”; or T40.4, “other synthetic narcotics”). Finally, if they write simply “drug 
overdose” without specifying any of the drugs involved, the contribution of the opioid analgesic 
will not be reflected in how the death is coded. The death will instead receive a code of “other 
and unspecified drugs” (T50.9)." A significant number of opioid related deaths are 
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miscategorized in this way (Ruhm, 2016). For this reason, I consider deaths classified by ICD-10 
code T50.9. In table A9, whether grouping all opioids and unspecified drugs, medicaments and 
biologicals deaths (ICD-10 Codes T40.0-T40.4, T40.6 & T50.9) or all opioids (ICD-10 Codes 
T40.0-T40.4, T40.6), the estimated treatment effect is similar.  
7. Conclusion 
This study builds on recent research (Meinhofer and Witman, 2018; Maclean and 
Saloner, 2019; Saloner et al., 2018; Wen et al., 2017) which documents increases in admissions 
to treatment and prescriptions for medications used to treat OUD in states that expanded 
Medicaid. I find that the Medicaid expansions led to a decrease in heroin related overdose deaths 
and an increase in methadone related overdose deaths. This study contributes to our 
understanding of the relationship between Medicaid and the opioid epidemic but faces important 
limitations including measurement error. I build further on recent research by presenting 
evidence of increases in methadone prescriptions covered by Medicaid in expanding states. This 
is the most likely channel (expanded access to treatment and medications for OUD) through 
which the expansion of Medicaid may reduce opioid related deaths. At the same time, increasing 
access to MAT can increase the diversion or misuse of these medications.  
An estimated 2.1 million Americans had an OUD in 2016 (SAMHSA, 2017). In 2015, an 
estimated 441,000 non-elderly adults were uninsured and addicted to opioids (Zur, 2017). Cost is 
one of many barriers to receiving treatment that individuals with OUD face, particularly those 
that lack health insurance. As Saloner and Barry (2018) note, targeting the supply of opioids may 
impact the number of newly addicted individuals but does not sufficiently alleviate the risk of 
overdose among the population already struggling with OUD. Evidence presented in this study 
22 
 
 
could inform future demand-oriented policy to alleviate the opioid epidemic. Demand-oriented 
policy could include patient outreach, education about the most effective types of treatment for 
OUD and increasing access to treatment for OUD.  
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9. Tables and Figures 
Table 1: Weighted Summary Statistics 
Variable Mean Std. Dev 
State Level (1999-2016)   
All Opioids  819.74 650.80 
All Opioids rate per 100k 6.76 4.43 
Heroin (T40.1) 201.86 237.48 
Heroin rate per 100k 1.57 1.92 
Other Opioids (T40.2) 362.43 333.83 
Other Opioids rate per 100k 2.89 2.21 
Methadone (T40.3) 140.14 120.66 
Methadone rate per 100k 1.21 0.85 
Synthetic Opioids (T40.4) 136.49 233.69 
Synthetic Opioids rate per 100k 1.25 2.23 
Other/Unspecified Narcotics (T40.6) 112.89 121.85 
Other/Unspecified Narcotics rate per 100k 0.96 1.21 
Medicaid Expansion 0.13 0.33 
County Level (2003-2016)   
All Opioids  70.39 107.40 
All Opioids rate per 100k 7.20 6.89 
Heroin (T40.1) 21.79 48.24 
Heroin rate per 100k 1.76 3.03 
Other Opioids (T40.2) 28.95 47.34 
Other Opioids rate per 100k 3.08 3.62 
Methadone (T40.3) 9.65 13.25 
Methadone rate per 100k 1.28 1.78 
Synthetic Opioids (T40.4) 11.23 34.99 
Synthetic Opioids rate per 100k 1.42 3.28 
Other/Unspecified Narcotics (T40.6) 11.35 40.76 
Other/Unspecified Narcotics rate per 100k 0.87 1.81 
Medicaid Expansion 0.16 0.37 
Notes: Sample excludes early expanding states with previous expansions of 
Medicaid (DC, MN, NJ and WA) 
 
 
 
 
 
 
 
  
1 
Table 2: Impact of Medicaid Expansion of Opioid Related Deaths    
  
All 
Opioids 
Heroin Other Opioids Methadone Synthetic 
Other 
Narcotics 
Baseline 0.115** -0.272** 0.0448 0.137** 0.237* 0.00559 
 (0.0565) (0.133) (0.100) (0.0671) (0.131) (0.145) 
       
Controls for Pertinent Laws 0.0789 -0.348*** 0.00457 0.0796 0.121 0.0127 
 (0.0500) (0.122) (0.0816) (0.0604) (0.148) (0.0897) 
       
Controls for Fentanyl Seizures 0.0344 -0.348*** 0.00637 0.0785 0.0304 -0.0627 
 (0.0490) (0.130) (0.0830) (0.0650) (0.144) (0.0836) 
       
Mean of Dependent 819.74 201.86 362.43 140.14 136.49 112.89 
N 846 846 846 846 846 846 
Notes: State year level data: 1999-2016. Population weighted Poisson regression estimates. Models include year fixed effect 
and state fixed effect. Expanding states with previous expansion have been dropped from the sample (DC, MN, NJ and WA). 
Controls include the natural log of the state population, age and demographic controls and the unemployment rate. Standard 
errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01 
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Table 3: Interaction       
  
All Opioids Heroin 
Other 
Opioids 
Methadone Synthetic 
Other 
Narcotics 
Medicaid Expansion*MAT 0.140** -0.362*** 0.0478 0.139** 0.264** 0.189 
 (0.0674) (0.125) (0.105) (0.0680) (0.129) (0.130) 
       
Other Expanding States -0.0384 0.256* 0.0349 0.140 0.141 -0.966*** 
 (0.0758) (0.141) (0.167) (0.145) (0.241) (0.278) 
 
      
Mean of Dependent 819.74 201.86 362.43 140.14 136.49 112.89 
N 846 846 846 846 846 846 
Notes: State year level data: 1999-2016. Population weighted Poisson regression estimates. Models include year 
fixed effect and state fixed effect. Expanding states with previous expansion have been dropped from the sample 
(DC, MN, NJ and WA). Controls include the natural log of the state population, age and demographic controls 
and the unemployment rate. Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, 
*** p<0.01 
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Table 4: Robustness to County Level Data       
  
All Opioids Heroin 
Other 
Opioids 
Methadone Synthetic 
Other 
Narcotics 
Baseline 0.0741 -0.0338 0.0609 0.400*** 0.425 -0.314 
 (0.0780) (0.233) (0.117) (0.0892) (0.291) (0.250) 
       
Controls for Pertinent Laws 0.0184 -0.247* 0.00187 0.310*** 0.230 -0.116 
 (0.0664) (0.127) (0.0718) (0.0878) (0.227) (0.103) 
       
Mean of Dependent 70.39 21.79 28.95 9.65 11.23 11.35 
N 41,853 41,853 41,853 41,853 41,853 41,853 
Notes: County year level data: 2003-2016. Population weighted Poisson regression estimates. Models include year 
fixed effect and state fixed effect. Expanding states with previous expansion have been dropped from the sample 
(DC, MN, NJ and WA). Controls include the natural log of the county population, age and demographic controls 
and the unemployment rate. Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** 
p<0.01 
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Table 5: Robustness to Functional Form (OLS)       
  
All Opioids Heroin Other Opioids Methadone Synthetic 
Other 
Narcotics 
Inverse Hyperbolic Sine (Death Rate)      
Medicaid Expansion 0.0785 -0.139 -0.0165 0.103* 0.117 0.0532 
 (0.0724) (0.101) (0.0834) (0.0540) (0.120) (0.0685) 
Natural Log (Death Rate + 1)       
Medicaid Expansion 0.0841 -0.0798 -0.0112 0.0770* 0.109 0.0351 
 (0.0732) (0.0793) (0.0646) (0.0396) (0.0966) (0.0509) 
Interaction Model             
Inverse Hyperbolic Sine (Death Rate)      
Medicaid Expansion*MAT 0.104 -0.253** -0.0275 0.140** 0.189 0.134** 
 (0.0828) (0.111) (0.0916) (0.0554) (0.134) (0.0628) 
 
      
Other Expanding States -0.0234 0.115 0.0113 0.0166 -0.0647 -0.223 
 (0.0944) (0.129) (0.105) (0.0804) (0.177) (0.181) 
Natural Log (Death Rate + 1)       
Medicaid Expansion*MAT 0.109 -0.163* -0.0156 0.105** 0.166 0.0980** 
 (0.0821) (0.0887) (0.0710) (0.0406) (0.110) (0.0471) 
 
      
Other Expanding States -0.0204 0.106 0.00285 0.0121 -0.0370 -0.175 
 (0.0986) (0.102) (0.0809) (0.0593) (0.139) (0.137) 
Mean of Dependent Before 
Transformation 
6.76 1.57 2.89 1.21 1.25 0.96 
N 846 846 846 846 846 846 
Notes: State year level data: 1999-2016. Population weighted OLS estimates. Models include year fixed effect and state 
fixed effect. Expanding states with previous expansion have been dropped from the sample (DC, MN, NJ and WA). 
Controls include pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs), age and demographic 
controls and the unemployment rate. Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** 
p<0.01 
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Table 6: Methadone - Medicaid State Drug Utilization 
Data   
Dependent 
Log Number of 
Prescriptions 
Log Medicaid 
Amount Reimbursed 
Log Units 
Reimbursed 
Baseline    
Medicaid Expansion 0.299** 0.179 0.205* 
 (0.116) (0.159) (0.116) 
Interaction    
Medicaid*MAT 0.367** 0.204 0.240* 
 (0.140) (0.184) (0.133) 
    
Other Expanding 0.0772 0.0963 0.113 
States (0.206) (0.220) (0.171) 
 
   
Mean of Dependent Before 
Transformation 
5,183.41 107,727.00 569,722.10 
N 2,009 1,857 1,475 
Notes: Medicaid State Drug Utilization data 2006-2016, state, quarterly level. Population weighted OLS 
estimates. Model includes year fixed effect, state fixed effect and control for the natural log of population. 
Quarterly Population data from Bureau of Economic Analysis Personal Income Summary 2010-2016. 
Annual Population data used as a proxy (2006-2010) from NCHS Bridged Race Population Estimates. 
Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01 
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Table 7: Alternate Specifications, Dependent variable: T40.4 Other Synthetic Narcotics 
  
Poisson 
OLS - Inverse 
Hyperbolic Sine 
OLS - Natural 
Log (Death Rate 
+ 1) 
(1) Baseline 0.230* 0.220* 0.187* 
 (0.128) (0.122) (0.0994) 
N 918 918 918 
 
   
(2) Controls for Pertinent Laws 0.107 0.104 0.0979 
 (0.149) (0.130) (0.104) 
N 918 918 918 
    
(3) Drop NH, MA, OH, MD -0.0502 -0.00220 0.00580 
 (0.152) (0.120) (0.0929) 
N 846 846 846 
    
(4) Full Sample with Control 0.00789 -0.0150 -0.00604 
for Fentanyl Seizures per Capita (0.146) (0.103) (0.0792) 
N 918 918 918 
 
   
Mean of Dependent Before Transformation 136.49 1.25 1.25 
Notes: State year level data: 1999-2016.  Population weighted regression estimates. Models include year fixed 
effect and state fixed effect. Controls include age and demographic controls and the unemployment rate. 
Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01 
1 
Table 8: Medicaid Expansion under the ACA 
State Expansion Date 
California 7/1/2011 
Connecticut 4/1/2010 
District of Columbia 7/1/2010 
Minnesota 3/1/2011 
New Jersey 4/14/2011 
Washington 1/3/2011 
Arizona 1/1/2014 
Arkansas 1/1/2014 
Colorado 1/1/2014 
Delaware 1/1/2014 
Hawaii 1/1/2014 
Illinois 1/1/2014 
Iowa 1/1/2014 
Kentucky 1/1/2014 
Maryland 1/1/2014 
Massachusetts 1/1/2014 
Michigan 4/1/2014 
Nevada 1/1/2014 
New Hampshire 8/15/2014 
New Mexico 1/1/2014 
New York 1/1/2014 
North Dakota 1/1/2014 
Ohio 1/1/2014 
Oregon 1/1/2014 
Rhode Island 1/1/2014 
Vermont 1/1/2014 
West Virginia 1/1/2014 
Alaska 9/1/2015 
Indiana 2/1/2015 
Montana 1/1/2016 
Louisiana 7/1/2016 
Pennsylvania 1/1/2015 
Source: Maclean and Saloner (2017) 
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Figure 1: Annual Opioid Overdose Deaths in the U.S. 
 
Notes: Data obtained from CDC WONDER Online Database, Multiple Cause of Death 1999-
2016. Deaths identified by International Classification of Disease, Tenth Revision (ICD-10) 
codes as follows: T40.0-T40.4, T40.6 (all opioids), T40.1 (heroin), T40.2 (other opioids), T40.3 
(methadone), T40.4 (other synthetic narcotics) and T40.6 (other/unspecified narcotics) 
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Figure 2: Event Study - Impact of Medicaid Expansions on Heroin Deaths 
 
Notes: State year level data: 1999-2016. Population weighted Poisson regression estimates. 
Model includes year fixed effect and state fixed effect. Expanding states with previous expansion 
have been dropped from the sample (DC, MN, NJ and WA). Controls include the natural log of 
the state population, age and demographic controls, the unemployment rate and other pertinent 
laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs). Standard errors are 
adjusted for clustering at the state level. 
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Figure 3: Event Study - Impact of Medicaid Expansions on Methadone Deaths 
 
Notes: State year level data: 1999-2016. Population weighted Poisson regression estimates. 
Model includes year fixed effect and state fixed effect. Expanding states with previous expansion 
have been dropped from the sample (DC, MN, NJ and WA). Controls include the natural log of 
the state population, age and demographic controls, the unemployment rate and other pertinent 
laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs). Standard errors are 
adjusted for clustering at the state level. 
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Figure 4: Event Study - Impact of Medicaid Expansions on Heroin Deaths: 2014 
Expanding States Only 
 
Notes: State year level data: 1999-2016. Population weighted Poisson regression estimates. 
Model includes year fixed effect and state fixed effect. All early and late expanding states 
dropped (treatment group includes only states that expanded Medicaid on Jan 1st 2014). Controls 
include the natural log of the state population, age and demographic controls, the unemployment 
rate and other pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs). 
Standard errors are adjusted for clustering at the state level. 
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Figure 5: Event Study - Impact of Medicaid Expansions on Methadone Deaths: 
2014 Expanding States Only
 
Notes: State year level data: 1999-2016. Population weighted Poisson regression estimates. 
Model includes year fixed effect and state fixed effect. All early and late expanding states 
dropped (treatment group includes only states that expanded Medicaid on Jan 1st 2014). Controls 
include the natural log of the state population, age and demographic controls, the unemployment 
rate and other pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs). 
Standard errors are adjusted for clustering at the state level. 
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Figure 6: Medicaid Amount Reimbursed for Methadone Prescriptions 
 
Notes: Medicaid State Drug Utilization data: 2006-2016. All early and late expanding states 
dropped (treatment group includes only states that expanded Medicaid on Jan 1st 2014). 
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Figure 7: Medicaid Number of Units Reimbursed for Methadone Prescriptions 
 
Notes: Medicaid State Drug Utilization data: 2006-2016. All early and late expanding states 
dropped (treatment group includes only states that expanded Medicaid on Jan 1st 2014). 
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Chapter 2. Opioid Use Disorder Treatment and Mortality: Evidence from Variation 
in Services Offered 
1. Introduction 
 In 2016, 2.1 million Americans struggled with opioid use disorder (OUD) (Department of 
Health and Human Services, 2017). From 1999-2016, over 367,000 deaths have been attributed 
to opioid overdose (CDC, 2018).7 Important questions remain regarding the effectiveness of 
treatment for OUD and whether sufficient levels of treatment are accessible. Further, among the 
population with OUD seeking treatment, often patients themselves do not know what type of 
treatment is most effective. In this study, I examine the impact that treatment facilities are having 
on the opioid related death rate within the counties they are located. I utilize variation in the 
location of substance abuse treatment facilities at the county level and variation in the services 
offered and insurance type accepted by those facilities to generate causal estimates of the impact 
of these services on opioid related mortality. I find significant heterogeneity across different 
types of treatment facilities with respect to the impact they're having on opioid related mortality. 
The opening of one additional substance abuse facility offering Medication Assisted Treatment 
(MAT) and accepting Medicaid reduces the county level opioid related death rate by about 0.6 to 
1 percent while one additional substance abuse facility of any other type does not have a 
statistically significant impact. 
Swensen (2015) exploits county level variation in the number of substance abuse 
treatment facilities and finds that a 10 percent increase in the number of treatment facilities leads 
to a 2 percent decline in the drug related mortality rate. This study builds on Swensen (2015) by 
examining the relationship between treatment centers and opioid related mortality. Further, I 
 
7 Including IDC-10 Codes: T40.0, T40.1, T40.2, T40.3, T40.4 and T40.6 
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exploit a new source of variation, that is, variation across different types of facilities. The 
American Society of Addiction Medicine (ASAM) recommends MAT to treat OUD (Grogan et 
al., 2016). MAT combines behavioral therapies and prescribed medications. MAT involves one 
of three medications approved by the FDA to treat OUD: buprenorphine, methadone, or 
naltrexone. Methadone and buprenorphine, the most commonly prescribed OUD medications, 
suppress the body’s cravings to use opioids and treat opioid withdrawal. Different OUD 
medications may be appropriate for different patients given differences in detox requirements, 
class of medication and frequency of dosage (Jones et al., 2018). 
While substance abuse treatment facilities are increasingly offering MAT services, most 
facilities did not offer these services as of 2016. Jones et al. (2018) examine data from the 
National Survey of Substance Abuse Treatment Services (N-SSATS) and find that in 2016, only 
4,950 of the 12,029 substance abuse facilities in the US report offering any form of MAT. There 
may also be a mismatch between insurance type accepted by substance abuse treatment facilities 
and the coverage of patients. In 2016, 7,466 of the 12,029 substance abuse facilities in the US 
reported accepting Medicaid (Jones et al., 2018). Among adult Medicaid beneficiaries, an 
estimated 12 percent have a substance use disorder (SUD) (Wachino, 2015). Approximately one 
out of every five Americans is covered by Medicaid (Rudowitz and Garfield, 2018).  
2. Literature Review 
Many studies have found improvements in patient outcomes following admission to 
treatment for SUD (Darke et al., 1996; Stewart et al., 2002; Hossop et al., 2003; Lu and 
McGuire, 2002; Swensen, 2015). Darke et al. (1996) find that heroin users who sought treatment 
or were active in treatment faced a substantially lower risk of overdose. Stewart et al. (2002) find 
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that admission to treatment led to reductions in non-fatal overdoses. Beyond the individual health 
risks, SUD imposes costs on society through health care use, use of public services, crime and 
traffic accidents (Maclean and Saloner, 2018). The opioid epidemic was estimated to cost the US 
economy $504 billion (2.8 percent of GDP) in 2015 (The Council of Economic Advisers, 
2017).From this perspective, treatment for SUD can reduce external costs. Bondurant et al. 
(2018) find that the opening of a treatment facility (at the county level) leads to a reduction in 
county level crime rates including homicide, aggravated assault, robbery, auto theft, and 
burglary.  
The opening or closing of a treatment facility impacts the availability of services to a 
given patient and can alter the cost of treatment to that patient. In 2015, 89 percent of all patients 
receiving treatment for a SUD received treatment in an outpatient setting (SAMHSA, 2017). 
This fact highlights the importance of the location of substance abuse treatment facilities and the 
potential mismatch between patient and facility with respect to services offered and insurance 
type accepted. Treatment facilities may be facing capacity constraints. Rapp et al. (2006) survey 
patients with SUD to identify potential barriers to receiving treatment. 20.2 percent of patients 
identified difficulty getting to and from treatment (Rapp et al., 2006). 34.3 percent of patients 
identified capacity constraints reporting they would be placed on a waiting list to receive 
treatment (Rapp et al., 2006).  
2.1 SUD Treatment and Health Insurance 
Cost can be a significant barrier to receiving treatment. White treatment facilities have 
traditionally relied on public grants and subsidies for funding, public and private insurance 
revenue has increased in importance in recent years (Bondurant et al., 2018). The Mental Health 
Parity and Addiction Equity Act of 2008 (MHPAEA) requires health insurance issuers provide 
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parity of benefits with respect to mental health and substance use disorder as would be provided 
for medical/surgical benefits (Centers for Medicare and Medicaid Services, 2018b). Dave and 
Mikerjee (2011) leverage state differences in parity laws prior to the MHPAEA; the authors find 
that state parity legislation increased treatment admissions, lowered the cost of treatment to the 
individual and reduced the probability that treatment visits were uninsured (Dave and Mikerjee, 
2011).  
The Affordable Care Act (ACA) bolstered the MHPAEA by requiring non-grand-
fathered health plans to cover ten essential health benefits which include mental health and 
substance use disorder treatment (Centers for Medicare and Medicaid Services, 2018a). In 2014, 
as the majority of provisions of the ACA were implemented, 20.2 million Americans struggled 
with a SUD (Center for Behavioral Health Statistics and Quality, 2015).  The expansion of 
Medicaid extended health insurance coverage to millions of Americans including 1.6 million 
individuals with a SUD (Grogan et al., 2016). Private market expansions further extended 
coverage to individuals with SUDs. New evidence points to unintended consequences resulting 
from the ACA and MHPAEA. Increased access to treatment requires vacancies at treatment 
facilities though treatment facilities may already be constrained by capacity. Maclean and 
Saloner (2018) examine the Massachusetts health reform of 2006 which expanded health 
insurance access and benefits with respect to SUDs. They find that the reform had little effect on 
treatment quality or access to treatment (Maclean and Saloner, 2018). 
More problematic may be the perverse incentives created by the ACA and MHPAEA. A 
scheme which has been called the “Florida Shuffle” involves treatment centers partnering up 
with brokers who find patients with SUDs and generous health insurance benefits. Treatment 
centers bill insurance issuers thousands of dollars per service like urine screening or counseling 
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session (Seville et al., 2017). These fraudulent treatment centers rely heavily on online searches 
and advertising and generally do not offer legitimate services that patients need. These fraudulent 
treatment centers have admitted patients that subsequently died of overdose (Seville et al., 2017). 
2.2 Efficacy of Methadone and Buprenorphine 
Methadone and buprenorphine have been thoroughly studied in the medical literature. 
Mattick et al. (2009) review 11 studies that compared opioid users treated with methadone 
therapy to no opioid replacement therapy. Patients were found have improved outcomes across a 
number of different measures including patient retention and subsequent drug screens with 
methadone therapy (Mattick et al., 2009). Patients receiving methadone maintenance were found 
to have reduced criminal activity and mortality, though these results were not statistically 
significant (Mattick et al., 2009). Mattick et al. (2014) review 31 different studies that test the 
efficacy of buprenorphine. A series of randomized clinical trials have shown buprenorphine to be 
more effective in terms of patient retention in treatment compared to placebo (Mattick et al., 
2014). Gowing et al. (2017) review 6 studies comparing buprenorphine and methadone treatment 
and conclude that despite somewhat limited evidence: “Buprenorphine and methadone in tapered 
doses appear to have similar efficacy in managing opioid withdrawal”. Connock et al. (2007) 
find that using a flexible dosing strategy, methadone maintenance therapy led to marginally 
better health gains compared to buprenorphine maintenance therapy. 
Increasingly, scientific evidence points to an increased probability of success for those 
with OUD receiving some type of opioid replacement therapy compared to no replacement 
therapy. In a clinical trial for an extended release formulation of buprenorphine, after 24 weeks, 
about 40 percent of patients receiving the treatment were abstaining from other opioid use 
compared to only 5 percent of patients receiving the placebo (National Academies of Sciences, 
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Engineering, and Medicine, 2018). The Prescription Opioid Addiction Treatment Study 
(POATS) followed patients dependent on prescription opioids over 42 months. Throughout 
multiple follow ups over 42 months, patients receiving opioid agonist therapy were found to 
have better outcomes (Weiss et al., 2015). Considering the social costs associated with OUD, we 
may also consider the cost effectiveness of MAT. Buprenorphine maintenance therapy costs 
about $6,000 per year (Wen et al., 2017). Methadone maintenance therapy is similar in cost in an 
outpatient setting. Connock et al. (2007) review of the buprenorphine and methadone literature 
concludes that both buprenorphine maintenance therapy and methadone maintenance therapy are 
more cost effective compared to no MAT.  
2.3 Access to Treatment and MAT 
 Barriers to receiving treatment include capacity constraints, distance and travel 
constraints and cost constraints (Gryczynski et al., 2011; Andrews et al., 2013; Rosenblum et al., 
2011; Sigmon, 2014). Jones et al. (2015) compare rates of opioid misuse to rates of treatment 
capacity and find a large shortcoming in combined buprenorphine and methadone treatment 
capacity. Access to buprenorphine and methadone is restricted due to the potential to misuse 
these medications. Specifically, the Drug Addiction Treatment Act of 2000 restricts the number 
of patients that certified physicians can treat with buprenorphine/naloxone to 30 patients in the 
first year following certification and 100 in subsequent years (Blum et al., 2016). These 
restrictions may be preventing patients with OUD from obtaining these medications, particularly 
in rural areas in which there are a limited number of prescribers (Blum et al., 2016). Due to these 
restrictions and other factors, access to MAT has not grown as quickly as the population of 
Americans struggling with OUD. Access to MAT is more likely problematic in rural counties 
than in urban counties. Stein et al. (2015) find that there were 11.4 opioid treatment programs 
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offering buprenorphine therapy in urban counties for every one such treatment program in rural 
counties.  
A particular concern in this study is the potential endogeneity of services offered by 
treatment facilities. For this reason, it is important to understand why treatment facilities may not 
offer MAT. Beyond the limitations associated with physician waivers, Olsen (2015) offers 
possible explanations for the opposition to offering MAT in the treatment community. Several 
addiction specialists from the Providers’ Clinical Support System for Medication Assisted 
Treatment (PCSS-MAT) identified three possibilities in the following quote from Olsen (2015): 
1. Owners of “drug-free” or “abstinence-based” facilities often do not have clinical 
backgrounds so have personal or ideological perspectives on addiction and its care.  
2. Treatment facilities may have financial incentives for restrictive clinical policies as 
relapse may result in re-admissions and additional revenue.  
3. The historical context of the “drug-free” model does not adequately differentiate between 
different substance use disorders. It is a useful framework for treating addiction to 
alcohol where available medications have limited effectiveness, and is virtually the only 
model for treating and preventing relapse to stimulants and cannabis where no 
medications exist. It is not a justifiable primary framework for the treatment of opioid 
addiction anymore.  
 
Beyond the restrictions affecting provision of MAT, these stigma and financial incentives may 
be contributing to a lack of patient access to MAT. Using an email survey of physicians, Huhn 
and Dunn (2017) identified concerns associated with prescribing buprenorphine that physicians 
acknowledged including: a lack of time for additional patients requiring MAT, a lack of belief in 
the use of agonist treatment and low reimbursement for time and services offered. 
 Following Swensen (2015) and Bondurant et al. (2018), I will conduct a number of 
ancillary tests to examine the validity of the research design. Of particular concern is the 
endogeneity of the opening/closing of treatment facilities and/or the endogeneity in choice of 
services offered. Grants, subsidies and public/private insurance funding for treatment is likely to 
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increase as drug abuse becomes more problematic. As Bondurant et al., (2018) argue: “Assuming 
these sources of financing generally increase with drug abuse and related problems, analyses of 
the effect of treatment provision on drug-related outcomes may understate the actual effect of 
treatment.”  (Bondurant et al., 2018) 
3. Data  
Data regarding the location, services offered and insurance type accepted by substance 
abuse treatment facilities comes from the Substance Abuse and Mental Health Services 
Administration (SAMHSA) National Survey of Substance Abuse Treatment Services (N-
SSATS). The N-SSATS is a survey of treatment facilities and so is not a universal database of 
these facilities. The response rate varies from year to year but is generally high. For example, in 
2010 the response rate was 91.4 percent and in 2013 the response rate was 94 percent (N-
SSATS, 2018). The N-SSATS contains a directory of each responding treatment facility that 
includes county identifiers and indicates what services are offered and what payment types are 
accepted by the facility.  
N-SSATS directories were scraped and compiled into datasets by the organization 
amfAR, the Foundation for AIDs research. Services offered and payment type accepted by 
treatment facilities are identified using facility codes. A treatment facility is classified as offering 
some form of MAT if any of the of the following facility codes appear: BMW (Buprenorphine 
Maintenance for Predetermined Time), BU (Buprenorphine Used in Treatment), BUM 
(Buprenorphine Maintenance), DB (Buprenorphine Detoxification), DM (Methadone 
Detoxification), METH (Methadone), MM (Methadone Maintenance), MMW (Methadone 
Maintenance for Predetermined Time), UBN (Prescribes/Administers Buprenorphine and/or 
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Naltrexone), VTRL (Vivitrol, Injectable Naltrexone). A treatment facility is identified as 
accepting Medicaid if the facility code MD appears in the directory. Finally, this methodology is 
used to characterize facilities offering buprenorphine, methadone, multiple forms of MAT and 
facilities offering MAT and accepting Medicaid.  
 
N-SSATS data is aggregated to the county, year level and merged with restricted use 
county level mortality data obtained from the National Association for Public Health Statistics 
and Information Systems (NAPHSIS). Opioid related deaths are identified using the 
International Classification of Disease, Tenth Revision (ICD-10) codes. All opioid deaths are 
classified as including ICD-10 codes: T40.0 (opium), T40.1 (heroin), T40.2 (other opioids), 
T40.3 (methadone), T40.4 (other synthetic narcotics) and T40.6 (other/unspecified narcotics). 
The opioid related death rate is calculated by aggregating opioid deaths to the county, year level, 
then dividing by the county population obtained from the National Center for Health Statistics 
(NCHS), Bridged-Race Population Estimate. 
I merge these data with a set of covariates. Demographic controls come from the NCHS 
Bridged-Race Population Estimate. These demographics include the fraction of the county 
population that is: white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old. Controls 
for economic conditions include the county unemployment rate obtained from the Bureau of 
Labor Statistics (BLS) Local Area Unemployment Statistics (LAUS) and county level per capita 
income obtained from the U.S. Bureau of Economic Analysis (BEA) regional data. 
I consider additional outcomes obtained from the Substance Abuse and Mental Health 
Services Administration’s Treatment Episode Data Set: Admissions (TEDS-A). The TEDS-A 
data contain records of admissions into treatment facilities. Following Maclean and Saloner 
(2019), I calculate the admissions rate per 100,000. The TEDS-A indicates whether methadone 
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or buprenorphine was involved in the client’s treatment plan. From 2010-2015, 7.8 percent of 
admissions involved either methadone or buprenorphine (SAMHSA, 2018). The use of 
methadone or buprenorphine is relatively well reported and is only missing in 4.3 percent of 
admissions records from 2010-2015 (SAMHSA, 2018). While health insurance status is also 
collected, from 2010-2015, insurance status is either missing or unknown for 56.8 percent of 
admissions (SAMHSA, 2018). Last, I examine the local economic impact of treatment facilities 
using the county level labor force participation rate from the American Community Survey 
(ACS) Employment Status 1-year estimates.  
4. Identification Strategy 
 I closely follow the identification strategy of Swensen (2015) and Bondurant et al. 
(2018), which relies on plausibly exogenous variation coming from the opening or closing of a 
treatment facility. I estimate the relationship between treatment facilities and the opioid related 
death rate using following equation: 
𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦𝑐,𝑡 = 𝛼 +  𝛽 ∗ 𝐹𝑎𝑐𝑖𝑙𝑖𝑡𝑦𝑐,𝑡−1 + 𝑋𝑐,𝑡 𝛾 +  𝛿𝐶 +  𝜌𝑇 + 𝜃𝑐,𝑡 +  𝜖𝑐,𝑡       (1) 
𝐹𝑎𝑐𝑖𝑙𝑖𝑡𝑦𝑐,𝑡−1 is the number of treatment facilities in county c in year t-1. 𝛿𝐶 is the county fixed 
effect and 𝜌𝑇 is the year fixed effect. 𝜃𝑐,𝑡 represents the state by year fixed effect. The 
identifying variation used in this study is visible in figures 1-3 which show the counties 
throughout the U.S. that experienced one or more openings of a substance abuse treatment 
facility (figure 1), one or more openings of a treatment facility offering MAT (figure 2) and one 
or more openings of a facility accepting Medicaid (figure 3). Whereas Swensen (2015) considers 
the impact of any treatment facility, I exploit variation across treatment facilities by measuring 
treatment facilities of different types as described in section 3. 𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦𝑐,𝑡 is the opioid related 
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death rate per 100,000 in county c in year t. These estimates are weighted by county population. 
Standard errors are adjusted for clustering at the county level. 𝑋𝑐,𝑡 is a vector of controls 
including demographic controls and controls for economic conditions. 
 To further examine the validity of this identification strategy, I estimate the following 
event study model: 
𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦𝑐,𝑡 = 𝛼 +  ∑ 𝐸𝑆 𝑐,𝑡
5
𝑡=−5
  𝛽 + 𝑋𝑐,𝑡 𝛾 +  𝛿𝐶 + 𝜌𝑡 + 𝜃𝑐,𝑡  +  𝜖𝑐,𝑡       (2) 
I define an event year as the year in which a substance abuse treatment facility opens in county c. 
I include a set of dummy variables within that county for each five years before and after the 
facility/facilities opening. Some counties experienced multiple openings and/or closings 
throughout the sample period. For this reason, I estimate event studies of two types. First, I 
estimate the impact of the opening of a treatment facility in counties in which no previous 
treatment facility of that type existed. Second, I estimate the impact of the opening of a treatment 
facility in counties which experienced only a single opening throughout the sample period.  
5. Results 
 In table 2, I examine the impact of substance abuse treatment facilities offering MAT on 
the opioid related death rate. The outcome variable, the opioid related death rate at the county 
year level, is transformed using the inverse hyperbolic sine function rather than the natural log 
function because of the non-negligible number of observations for which the outcome variable 
equals zero. For each type of facility, the opening of a treatment facility offering MAT services 
decreases the county level opioid related death rate. The opening of one substance abuse facility 
offering MAT is estimated to reduce the county level opioid related death rate by about 0.2 to 0.6 
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percent (column 1). One additional substance abuse facility offering MAT represents a 10.6 
percent increase compared to the existing mean capacity. The opening of one substance abuse 
facility offering MAT and accepting Medicaid is estimated to reduce the county level opioid 
related death rate by about 0.6 to 0.95 percent (column 2). The opening of one substance abuse 
facility offering two or more forms of MAT and accepting Medicaid has a similar estimated 
effect (column 4) to the opening of one substance abuse facility offering MAT and accepting 
Medicaid. Whether a treatment facility offers one or multiple forms of MAT, a facility opening 
has a larger negative impact on the county death rate if that facility also accepts Medicaid.  
In table 3, I compare facilities offering buprenorphine and methadone. The opening of a 
treatment facility offering buprenorphine is estimated to be more impactful on the opioid related 
death rate compared to the opening of a treatment facility offering methadone (columns 1 and 3). 
The opening of a treatment facilities offering buprenorphine is estimated to have a larger 
negative impact on the opioid related death rate if that facility also accepts Medicaid (column 2). 
The opening of a treatment facilities offering buprenorphine and accepting Medicaid leads to a 
reduction in the opioid related death rate of about 0.8 percent. In table 4, I compare the types of 
treatment facilities estimated to be the most impactful on the opioid related death rate to all other 
substance abuse treatment facilities not of that type. The opening of a treatment facility accepting 
Medicaid and offering buprenorphine, some form of MAT, or two or more forms of MAT leads 
to about a 0.8 to 1 percent reduction in the county level opioid related death rate (column 1). The 
opening of any treatment facility not of that type does not have a statistically significant impact 
on the county level opioid related death rate (column 2). The estimates are visible in figure 5. 
The opening of a treatment facility accepting Medicaid and offering MAT has a much larger 
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negative impact on the opioid related death rate compared the opening of a treatment facility 
accepting Medicaid or offering MAT.   
5.1 Analysis of Treatment Episode Data Set: Admissions 
 Next, I consider outcomes from the TEDS-A. The TEDS-A data does not have county 
identifiers. Rather, the TEDs-A contains identifiers for the state and core based statistical area 
(CBSA) of the treatment admission. First, I aggregate the TEDS-A and the N-SSATS to the state 
year level and merge the two data sets. In table 5, I examine admission by the primary substance 
abuse problem restricting the sample to admissions related to OUD. Facilities that offer two plus 
forms of MAT and accept Medicaid had the largest impact on the opioid related admission rate. 
The opening of one such facility was estimated to increase the state level OUD admissions rate 
by about 0.5 per 100,000. 
 Second, I aggregate to the TEDS-A to the CBSA year level. Using the CBSA to FIPS 
County Crosswalk file from the National Bureau of Economic Research (NBER), I match 
treatment facilities with county identifiers to a CBSA. CBSA population estimates were obtained 
from the U.S. Census Bureau (2019). In panel A of table 6, I restrict the TEDS-A sample to 
admissions in which methadone or buprenorphine was involved in the client’s treatment plan 
(hereafter referred to as admission involving MAT). Facilities offering some form of MAT and 
accepting Medicaid have the largest effect on the admission involving MAT rate. The opening of 
such a treatment facility is estimated to increase the admission involving MAT rate by about 0.6 
per 100,000.  
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5.2 Event Study Analysis 
 In order to test the validity of the research design, I present event studies that examine the 
impact of a treatment facility opening on the opioid related death rate in each year before and 
after the opening. The event study evidence, in general, alleviates concerns about the 
endogeneity of the opening of a treatment facility. Figure 6 shows the impact of one or more 
substance abuse treatment facilities opening within counties with no previous treatment facility, 
on the county level opioid related death rate. While there are no visible trends leading up to the 
opening(s), the opioid related death rate declines, most prominently 2-5 years after the 
opening(s). I restrict the scope of the event studies to substance abuse treatment facilities that 
accept Medicaid. Within counties that had no previous treatment facility accepting Medicaid 
experiencing one or more openings (figure 7), again no trends appear in the years leading up to 
the opening(s). The opening(s) then lead to a decrease in the opioid related death rate.   
 Next, I apply the event study framework to the opening of treatment facilities offering 
MAT. In the years leading up to the opening of one or more treatment facilities offering some 
MAT (figure 8) in counties with no facility offering MAT, no effect appears. The opioid related 
death rate then declines in years 1-4 after the opening(s). In figure 9, I examine counties that 
experience a single opening of a treatment facility offing MAT and accepting Medicaid. Prior to 
the opening, no effect appears. A small decrease in the opioid death rate appears following the 
opening, however, confidence intervals are large and contain a zero-coefficient estimate. Finally, 
in figures 10 and 11, I apply both event study frameworks to facilities offering two of more 
forms of MAT. Throughout the event studies, coefficient estimates are close to zero in the years 
leading up to the opening of a treatment facility across facility types. While the event studies do 
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restrict the identifying variation, they offer evidence in support of the validity of the 
identification strategy used throughout this study.  
5.3 Robustness 
In table A1, it appears that the primary results presented in this study are robust when 
estimated using alternate measures of the outcome variable, unweighted models and to different 
functional forms. These alternate specifications include the natural log transformation of the 
opioid related death rate (panel A)8, unweighted OLS (panel B) and population weighted Poisson 
models (panel C).9 Next, I test potential reverse causality of this relationship between treatment 
facilities and the opioid related death rate. I construct an indicator variable equal to one if one or 
more treatment facilities has opened in county c in year t and equal to zero otherwise. I estimate 
the following linear probability model: 
𝑂𝑝𝑒𝑛𝑖𝑛𝑔𝑐,𝑡 =  𝛼 +  𝛽 ∗ 𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦𝑐,𝑡−1 + 𝑋𝑐,𝑡 𝛾 +  𝛿𝐶 +  𝜌𝑡 + 𝜃𝑐,𝑡  + 𝜖𝑐,𝑡       (3) 
Table A7 presents the results from the test of reverse causality. I present estimates from equation 
3 with a one and a two-year lag of the measure of the opioid related death rate. I find two 
significant result of opposite sign from twelve total specifications. Overall, the county level 
opioid related death rate was not found to predict the opening of treatment facilities. Next, I 
examine the potential for changes in the composition of the county population in response to the 
opening/closing of treatment facilities. In table A8, I put county demographic measures on the 
 
8 One is added to the opioid related death rate prior to the log transformation to avoid missing observations 
9 Poisson regressions are estimated using the ppmlhdfe Stata command developed by Correia et al. (2019) while 
OLS regressions are estimated using reghdfe Stata command developed by Correia (2017) 
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left-hand side and find that overall, the opening/closing of treatment facilities does not explain 
any potential compositional changes in the county population.  
5.4 Heterogeneity 
In table 7, I compare substance abuse treatment taking place in Florida to the rest of the 
U.S. In 5 of 6 specifications, the coefficient of interest is positive when the sample is restricted to 
counties within Florida and negative when the sample consists of all counties outside of Florida. 
These results may be indicative of the perverse incentives created by the ACA and MHPAEA. 
While these results do not provide an identification strategy to test for fraud in the treatment 
industry in Florida, they are suggestive of such effects. There are accounts of fraud in the 
treatment industry in the media on a case by case basis but no published research of broader 
scope to date (Seville et al., 2017). 
In table A2, I explore the heterogeneity of these effects by gender. The opening of a 
treatment facility offering some MAT and accepting Medicaid has the largest negative impact on 
the opioid related death rate of females. The opening of such a treatment facility has less of an 
impact of the male opioid related death rate. The population weighted mean male opioid related 
death rate is about twice that of the female opioid related death rate. In table A3, I explore the 
heterogeneity of these effects by race. When considering the white and black opioid related death 
rates, again, the most effective type of treatment facility appears to be facilities offering MAT 
and accepting Medicaid. The weighted mean white opioid related death rate is about twice that of 
the black death rate and the Hispanic death rate. Finally, I explore the heterogeneity of these 
effects by county size. I split the data by county population categorizing counties as urban, 
medium or rural. In table A4, it appears that treatment facility openings have a larger negative 
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impact in rural counties though the coefficient of interest is no longer significant. This may be 
explained by a lack of identifying variation as there are fewer openings in rural counties 
throughout the sample period. 
5.5 Other Economic Outcomes 
Given the economic cost of the opioid epidemic, changes in treatment capacity may 
impact local economic outcomes. In table A5, I consider the impact of treatment facilities on the 
labor force participation rate using two different measures. The first measure of the labor force 
participation rate comes from the ACS Employment Status 1-Year Estimates. This dataset does 
not include every county in the US. The second measure contains the majority of US counties. It 
was constructed by the author taking the county labor force as a count, obtained from the BLS, 
and dividing by the county level working age population from the NCHS. Using both measures, 
treatment facilities appear to have a positive economic impact on the communities they serve. 
Facilities offering MAT and accepting Medicaid led to the largest increases in the labor force 
participation rate. The opening of one such facility is estimated to increase the labor force 
participation rate by about 0.08-0.09 percent. In table A6, I consider a number of measures of 
income from the ACS Income in the past 12 months 1-Year Estimates. While the effect size is 
small, the opening of a treatment facility appears to have a positive impact on median and mean 
county income.  
6. Conclusion 
In this study, I find that the opening of a substance abuse treatment facility has a negative 
impact on the opioid related death rate within the county of the opening. There is substantial 
heterogeneity when comparing different types of treatment facilities. The opening of a treatment 
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facility offering at least some form of MAT and accepting Medicaid is estimated to reduce the 
county opioid related death rate by about 0.9 to 1.1 percent while the opening of any other type 
of treatment facility does not have a statistically significant impact. Treatment facilities 
accepting Medicaid and offering MAT were also found to have a larger positive impact on 
treatment admissions rates and on local economic outcomes. 
Mental health parity legislation along with the ACA has increasing the prominence of 
public and private insurance in providing funding for treatment of SUD. Medicaid is the single 
largest payer for mental health services in the U.S. (Centers for Medicare and Medicaid Services, 
2019). From the perspective of a patient seeking treatment for OUD, increasing treatment 
capacity can remove or reduce some of the barriers to receiving treatment that patient may face. 
These barriers could include cost related to distance/travel, insurance type mismatch or a lack of 
services available to treat OUD. Results presented in this paper suggest that the existing capacity 
for treatment of OUD in the U.S. may not be sufficient. Specifically, this applies to Medicaid 
beneficiaries seeking treatment for OUD. 
 
  
61 
 
 
7. References 
American Community Survey. 2005-2016. Employment Status 1-year estimates. 
 
American Community Survey. 2005-2016. Income in the past 12 months 1-year estimates.  
 
amfAR, The Foundation for AIDs Research. 2005-2016. Opioid & Health Indicators Database. 
https://opioid.amfar.org/about/sources 
 
Andrews, Christina M., Hee-Choon Shin, Jeanne C. Marsh, and Dingcai Cao. 2013. "Client and 
Program Characteristics Associated with Wait Time to Substance Abuse Treatment Entry." The 
American Journal of Drug and Alcohol Abuse 39 (1): 61-68. 
 
Bureau of Labor Statistics. 2005-2016. Local Area Unemployment Statistics. 
 
Blum, Kenneth, Mark Gold, H. Westley Clark, Kristina Dushaj, and Rajendra D. Badgaiyan. 
2016. "Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone 
Treatment?" Substance Use & Misuse 51 (12): 1674-679. 
 
Bondurant, Samuel R., Lindo, Jason M. and Swensen, Isaac D. 2018. “Substance abuse treatment 
centers and local crime”. Journal of Urban Economics 104: 124-133. 
 
Center for Behavioral Health Statistics and Quality. 2015. Behavioral Health Trends: Results 
from the 2014 National Survey on Drug Use and Health, Center for Behavioral Health Statistics 
and Quality: Rockville, MD. 
 
Centers for Disease Control and Prevention, National Center for Health Statistics. 1999-2016. 
Multiple Cause of Death on CDC WONDER Online Database, released December, 2017. Data 
are from the Multiple Cause of Death Files. 
 
Centers for Disease Control and Prevention, National Center for Health Statistics 1999-2016. 
Bridged-Race Population Estimates, United States July 1st resident, population by state, county, 
age, sex, bridged-race, and Hispanic origin.  
 
Centers for Medicare and Medicaid Services. 2019. “Behavioral Health Services.” 
https://www.medicaid.gov/medicaid/benefits/bhs/index.html  
 
Centers for Medicare and Medicaid Services. 2018. “Information on Essential Health Benefits 
(EHB) Benchmark Plans”. 
https://www.cms.gov/cciio/resources/data-resources/ehb.html 
 
Centers for Medicare and Medicaid Services. 2018. “The Mental Health Parity and Addiction 
Equity Act (MHPAEA)”. https://www.cms.gov/cciio/programs-and-initiatives/other-insurance-
protections/mhpaea_factsheet.html 
 
62 
 
 
Connock, M, Juarez-Garcia, A, Jowett, S, Frew, E, Liu, Z, Taylor, R J, Fry-Smith, A, Day, E, 
Lintzeris, N, Roberts, T, Burls, A, and Taylor, R S. 2007. "Methadone and Buprenorphine for the 
Management of Opioid Dependence: A Systematic Review and Economic Evaluation." Health 
Technology Assessment 11 (9): 1-171, Iii-iv. 
 
Correia, Sergio. 2017. “Linear Models with High-Dimensional Fixed Effects: An Efficient and 
Feasible Estimator” Working Paper.  
 
Correia, Sergio, Paulo Guimarães and Thomas Zylkin. 2019. "ppmlhdfe: Fast Poisson Estimation 
with High-Dimensional Fixed Effects," Papers 1903.01690, arXiv.org, revised Mar 2019. 
 
Dave, Dhaval, and Swati Mukerjee. 2011. "Mental Health Parity Legislation, Cost-sharing and 
Substance-abuse Treatment Admissions." Health Economics 20 (2): 161-183. 
 
Darke, Shane, Joanne Ross, and Wayne Hall. 1996. "Overdose among Heroin Users in Sydney, 
Australia: I. Prevalence and Correlates of Non‐fatal Overdose." Addiction 91 (3): 405-11. 
 
Gossop, Michael, John Marsden, Duncan Stewart, and Tara Kidd. 2003. "The National 
Treatment Outcome Research Study (NTORS): 4–5 year Follow‐up Results." Addiction 98 (3): 
291-303. 
 
Gowing, Linda, Robert Ali, Jason M White, and Dalitso Mbewe. 2017. "Buprenorphine for 
Managing Opioid Withdrawal." The Cochrane Database of Systematic Reviews 2 (2): 
CD002025. 
 
Grogan, Colleen M., Christina Andrews, Amanda Abraham, Keith Humphreys, C., Harold A. 
Pollack, Bikki Tran Smith and Peter D. Friedmann. 2016. “Treatment And Opioid Use Disorder 
Medications Survey Highlights Differences In Medicaid Coverage For Substance Use” Health 
Affairs 35 (12): 2289-2296. 
 
Gryczynski, Schwartz, Salkever, Mitchell, and Jaffe. 2011. "Patterns in Admission Delays to 
Outpatient Methadone Treatment in the United States." Journal of Substance Abuse 
Treatment 41 (4): 431-39. 
 
Huhn, Andrew S. and Kelly E. Dunn. 2017. "Why Aren't Physicians Prescribing More 
Buprenorphine?" Journal of Substance Abuse Treatment 78 (C): 1-7. 
 
Jones, Austin, Brian Honermann, Alana Sharp and Gregorio Millett. 2018. “Where Multiple 
Modes Of Medication-Assisted Treatment Are Available," Health Affairs Blog, January 9. 
 
Jones, Christopher M, Melinda Campopiano, Grant Baldwin, and Elinore Mccance-Katz. 2015. 
"National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted 
Treatment." American Journal of Public Health 105 (8): E55-63. 
 
63 
 
 
Lu, Mingshan, and Thomas G. Mcguire. 2002. "The Productivity of Outpatient Treatment for 
Substance Abuse." The Journal of Human Resources 37 (2): 309-35. 
 
Mattick, Richard P, Courtney Breen, Jo Kimber, and Marina Davoli. 2009. "Methadone 
Maintenance Therapy versus No Opioid Replacement Therapy for Opioid Dependence." The 
Cochrane Database of Systematic Reviews (3): CD002209. 
 
Mattick, Richard P, Courtney Breen, Jo Kimber, and Marina Davoli. 2014. "Buprenorphine 
Maintenance versus Placebo or Methadone Maintenance for Opioid Dependence." The Cochrane 
Database of Systematic Reviews (2): CD002207. 
 
Maclean, Johanna Catherine, and Brendan Saloner. 2018. "Substance Use Treatment Provider 
Behavior and Healthcare Reform: Evidence from Massachusetts." Health Economics 27 (1): 76-
101. 
 
Maclean, Johanna Catherine, and Brendan Saloner. 2019. "The Effect of Public Insurance 
Expansions on Substance Use Disorder Treatment: Evidence from the Affordable Care 
Act." Journal of Policy Analysis and Management 38 (2): 366-393. 
 
National Academies of Sciences, Engineering, and Medicine. 2018.  Advancing Therapeutic 
Development for Pain and Opioid Use Disorders Through Public-Private Partnerships: 
Proceedings of a Workshop. National Academies Press. https://doi.org/10.17226/25060  
 
National Association for Public Health Statistics and Information Systems. 2005-2016. 
Mortality - Multiple cause of death, states and all counties. 
 
National Bureau of Economic Research. 2015. CBSA to FIPS County Crosswalk. 
 
Olsen, Yngvild. 2015. “Ask the PCSS-MAT Experts: Addressing Challenging Issues in 
Addiction Medicine: "Abstinence Based" Treatment Centers” ASAM Magazine. April 10.  
https://www.asam.org/resources/publications/magazine/read/article/2015/04/10/abstinence-
based-treatment-centers   
 
Rapp, Xu, Carr, Lane, Wang, and Carlson. 2006. "Treatment Barriers Identified by Substance 
Abusers Assessed at a Centralized Intake Unit." Journal of Substance Abuse Treatment 30 (3): 
227-35. 
 
Rosenblum, Andrew, Charles M. Cleland, Chunki Fong, Deborah J. Kayman, Barbara 
Tempalski, and Mark Parrino. 2011. "Distance Traveled and Cross-State Commuting to Opioid 
Treatment Programs in the United States." Journal of Environmental and Public Health 2011: 
204-13. 
 
Rudowitz, Robin and Rachel Garfield. 2018. “10 Things to Know about Medicaid: Setting the 
Facts Straight”. The Henry J. Kaiser Family Foundation. Mar 12. 
 
64 
 
 
Seville, Lisa Riordan, Anna R. Schecter and Hannah Rappleye. 2017. “Florida’s Billion-Dollar 
Drug Treatment Industry Is Plagued by Overdoses, Fraud” NBC News. June 25. 
Sigmon, Stacey C. 2014. "Access to Treatment for Opioid Dependence in Rural America: 
Challenges and Future Directions." JAMA Psychiatry 71 (4): 359-60. 
 
Stein, Bradley D., Rosalie Liccardo Pacula, Adam J. Gordon, Rachel M. Burns, Douglas L. 
Leslie, Mark J. Sorbero, Sebastian Bauhoff, Todd W. Mandell, and Andrew W. Dick. 2015. 
"Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private 
Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and 
Rural Counties." Milbank Quarterly 93 (3): 561-83. 
 
Stewart, Gossop, and Marsden. 2002. "Reductions in Non-fatal Overdose after Drug Misuse 
Treatment: Results from the National Treatment Outcome Research Study (NTORS)." Journal of 
Substance Abuse Treatment 22 (1): 1-9. 
 
Substance Abuse and Mental Health Services Administration. 2016. “Medication-Assisted 
Treatment of Opioid Use Disorder” SMA16-4892PG. April 5. 
 
Substance Abuse and Mental Health Services Administration. 2017. National Survey of 
Substance Abuse Treatment Services (N-SSATS): 2015. Data on Substance Abuse Treatment 
Facilities. BHSIS Series S-88, HHS Publication No. (SMA) 17-5031, 2017. 
 
Substance Abuse and Mental Health Services Administration. 2005-2016. National Survey of 
Substance Abuse Treatment Services (N-SSATS). 
 
Substance Abuse and Mental Health Services Administration, Center for Behavioral Health 
Statistics and Quality. 2015. National Survey on Drug Use and Health (NSDUH). 
 
Substance Abuse and Mental Health Services Administration. 2005-2017. Treatment Episode 
Data Set: Admissions (TEDS-A). 
 
Swensen, Isaac D. 2015. "Substance-abuse Treatment and Mortality." Journal of Public 
Economics 122: 13-30.  
The Council of Economic Advisers. 2017. “The Underestimated Cost of the Opioid Crisis”. 
November. 
 
United States Bureau of Economic Analysis. 2005-2016. Regional Data. Local Area Personal 
Income and Employment. CA1 Personal Income Summary: Personal Income, Population, Per 
Capita Personal Income. 
 
United States Census Bureau. 2006-2017. Metropolitan and Micropolitan Statistical Areas 
Population Totals: Annual Estimates of the Resident Population. 
 
United States Department of Health and Human Services. 2019. “The Opioid Epidemic by the 
Numbers”. 
65 
 
 
 
Wachino, Vikki. 2015. “New Medicaid Initiative Improves Access to Substance Use Disorder 
Treatment” CMS Deputy Administrator and Director for the Center for Medicaid and CHIP 
Services. July 27. 
 
Weiss, Potter, Griffin, Provost, Fitzmaurice, Mcdermott, Srisarajivakul, Dodd, Dreifuss, 
Mchugh, and Carroll. 2015. "Long-term Outcomes from the National Drug Abuse Treatment 
Clinical Trials Network Prescription Opioid Addiction Treatment Study." Drug and Alcohol 
Dependence 150: 112-19. 
 
Wen, Hefei M., Jason F. Hockenberry, Tyrone G. Borders, and Benjamin Druss. 2017. "Impact 
of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use 
Disorder Treatment." Medical Care 55 (4): 336-41. 
 
  
66 
 
 
8. Tables and Figure 
Table 1   
Summary Statistics 
Variable Mean Std. Dev 
Facilities Providing Substance Abuse Services 39.24 77.29 
Facilities Providing Substance Abuse Services and Accepting 
Medicaid 
16.96 27.58 
Facilities Providing Some Medication Assisted Treatment 9.73 17.50 
Facilities Providing Some Medication Assisted Treatment and 
Accepting Medicaid 
5.80 10.86 
Facilities Providing at Least Two Different Forms of 
Medication Assisted Treatment 
6.19 12.46 
Facilities Providing at Least Two Different Forms of 
Medication Assisted Treatment and Accepting Medicaid 1.81 4.24 
Facilities Providing Buprenorphine 4.58 9.24 
Facilities Providing Buprenorphine and Accepting Medicaid 2.53 5.55 
Facilities Providing Methadone 4.58 8.91 
Facilities Providing Methadone and Accepting Medicaid 3.10 6.80 
All Opioids Death rate per 100k 7.52 7.08 
Fraction Ages 0-15 0.21 0.03 
Fraction Ages 16-35 0.26 0.04 
Fraction Ages 35-64 0.39 0.03 
Fraction Female 0.51 0.01 
Fraction White 0.79 0.15 
Fraction Black 0.13 0.14 
Unemployment Rate 6.74 2.63 
Log Per Capita Income 10.62 0.28 
Labor Force Participation Rate (ACS Employment) 0.66 0.05 
Labor Force Participation Rate (BLS) 0.63 0.06 
Median Household Income 61,586 15,644 
Median Non-Family Household Income 38,221 10,065 
Mean Household Income 82,323 20,446 
Mean Non-Family Household Income 52,275 13,419 
Notes: Data: 2005-2016. Summary statistics are weighted by county population. 
Florida excluded from sample. Data sources: N-SSATS, NAPHSIS, NCHS, ACS, 
BLS, BEA 
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Table 2     
Treatment Facilities Offering MAT   
  
Facilities 
Providing Some 
MAT 
Facilities 
Providing MAT 
and Accepting 
Medicaid 
Facilities 
Providing Two or 
More Forms of 
MAT 
Facilities Providing 
Two plus forms of 
MAT and 
Accepting 
Medicaid 
County FE and Year FE -0.00629*** -0.00608* -0.00191** -0.00698* 
 (0.00125) (0.00318) (0.000795) (0.00388) 
N 33,798 33,798 33,798 33,798 
 
    
Include State by Year FE -0.00293 -0.00945*** -0.00137 -0.0112*** 
 (0.00248) (0.00360) (0.00117) (0.00397) 
N 33,769 33,769 33,769 33,769 
 
    
Include Demographic Controls -0.00229 -0.00884*** -0.00115 -0.00975** 
 (0.00252) (0.00336) (0.00112) (0.00401) 
N 33,769 33,769 33,769 33,769 
 
    
Include Controls for -0.00231 -0.00892*** -0.00112 -0.00958** 
Economic Conditions (0.00261) (0.00342) (0.00113) (0.00413) 
N 33,197 33,197 33,197 33,197 
Mean of Dependent Before 
Transformation 
7.52 7.52 7.52 7.52 
Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per 100,000. Inclusion of 
controls and fixed effects varied by row. Treatment facilities are a count variable per county per year by type of 
facility. These estimates are weighted by county population. Standard errors in parenthesis are adjusted for clustering 
at the county level. * p<0.10, ** p<0.05, *** p<0.01 
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Table 3     
Treatment Facilities Classified by Medication Offered   
  
Facilities 
Offering 
Buprenorphine 
Facilities Offering 
Buprenorphine and 
Accepting 
Medicaid 
Facilities Offering 
Methadone 
Facilities Offering 
Methadone and 
Accepting Medicaid 
County FE and Year FE -0.00266 -0.00768*** 0.00383* 0.00198 
 (0.00168) (0.00178) (0.00206) (0.00329) 
N 33,809 33,809 33,809 33,809 
 
    
Include State by Year FE -0.00435*** -0.00862*** 0.000103 0.000962 
 (0.00123) (0.00147) (0.00218) (0.00328) 
N 33,776 33,776 33,776 33,776 
 
    
Include Demographic Controls -0.00410*** -0.00810*** -0.00124 -0.000736 
 (0.00118) (0.00140) (0.00197) (0.00308) 
N 33,776 33,776 33,776 33,776 
 
    
Include Controls for -0.00391*** -0.00770*** -0.000976 -0.000398 
Economic Conditions (0.00126) (0.00146) (0.00196) (0.00305) 
N 33,204 33,204 33,204 33,204 
Mean of Dependent Before 
Transformation 
7.52 7.52 7.52 7.52 
Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per 100,000. Inclusion of 
controls and fixed effects varied by row. Treatment facilities are a count variable per county per year by type of facility. 
These estimates are weighted by county population. Standard errors in parenthesis are adjusted for clustering at the county 
level. * p<0.10, ** p<0.05, *** p<0.01 
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Table 4   
Comparing Treatment Facilities to all others not of the Type  
  
Facilities of that 
Type 
All other Facilities Not 
of that Type 
Panel A   
Facilities Offering Some MAT -0.00892*** -0.000811 
and Accepting Medicaid (0.00342) (0.00102) 
 
  
Panel B   
Facilities Offering at least 2 Forms -0.00958** -0.000999 
of MAT and Accepting Medicaid (0.00413) (0.000976) 
 
  
Panel C   
Facilities Offering Buprenorphine  -0.00770*** -0.000652 
and Accepting Medicaid (0.00146) (0.00112) 
N 33,197 33,197 
Mean 7.52 7.52 
Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per 
100,000. Controls include the fraction of the county population that are white, black, female, ages 
0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and the natural log of per capita 
income. Treatment facilities are a count variable: number in a county by year. Models include 
county, year and state by year fixed effects. These estimates are weighted by county population. 
Standard errors in parenthesis are adjusted for clustering at the county level. * p<0.10, ** p<0.05, 
*** p<0.01 
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Table 5       
Opioid Use Treatment Admissions Rate by Primary Substance Abuse Problem - State Year 
Level Data   
  
Substance 
Abuse 
Facilities 
SA Facilities 
Accepting 
Medicaid 
Facilities 
Providing 
Some MAT 
Facilities 
Providing 
MAT and 
Accepting 
Medicaid 
Facilities 
Providing Two 
or More Forms 
of MAT 
Facilities 
Providing Two 
plus forms MAT 
and Accepting 
Medicaid 
Panel A: All Opiates -0.117 -0.0361 0.0750 0.192*** 0.218* 0.486** 
 (0.108) (0.150) (0.101) (0.0620) (0.110) (0.213) 
N 498 498 498 498 498 498 
Mean 144.91 144.91 144.91 144.91 144.91 144.91 
 
      
Panel B: Heroin -0.0900 -0.0835 -0.00277 0.00196 0.129 0.335* 
 (0.0925) (0.102) (0.0588) (0.0650) (0.0957) (0.167) 
N 493 493 493 493 493 493 
Mean 100.63 100.63 100.63 100.63 100.63 100.63 
 
      
Panel C: Other Opiates -0.0285 0.0455 0.0747 0.182*** 0.0858 0.144** 
Excluding Methadone (0.0356) (0.0577) (0.0775) (0.0506) (0.0652) (0.0604) 
N 497 497 497 497 497 497 
Mean 43.53 43.53 43.53 43.53 43.53 43.53 
Notes: Dependent variable - treatment admission rate per 100,000 where primary substance abuse problem is opioid use. Controls 
include the fraction of the state population that are white, black, ages 0-15, ages 16-34 and ages 35-64 years old and the unemployment 
rate. Treatment facilities are a count variable per state per year by type of facility. Models include state and year fixed effects. These 
estimates are weighted by state population. Standard errors in parenthesis are adjusted for clustering at the state level. * p<0.10, ** 
p<0.05, *** p<0.01 
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Table 6       
Opioid Use Disorder Treatment Admissions Rate - Core Based Statistical Area   
  
Substance 
Abuse 
Facilities 
SA Facilities 
Accepting 
Medicaid 
Facilities 
Providing 
Some MAT 
Facilities 
Providing 
MAT and 
Accepting 
Medicaid 
Facilities 
Providing Two 
or More Forms 
of MAT 
Facilities 
Providing Two 
plus forms MAT 
and Accepting 
Medicaid 
Panel A -0.0829 -0.227** 0.409*** 0.599*** 0.158 0.289*** 
Admissions Involving MAT (0.106) (0.114) (0.134) (0.134) (0.152) (0.0368) 
N 1,362 1,362 1,362 1,362 1,362 1,362 
Mean 45.61 45.61 45.61 45.61 45.61 45.61 
 
      
Panel B -0.193 -0.283 0.120 0.114 0.0101 0.0632 
Admissions for OUD (0.149) (0.186) (0.238) (0.350) (0.200) (0.123) 
N 1,362 1,362 1,362 1,362 1,362 1,362 
Mean 154.96 154.96 154.96 154.96 154.96 154.96 
Notes: Dependent variable - treatment admission rate per 100,000 where primary substance abuse problem is opioid use. Treatment 
facilities are a count variable per CSBA per year by type of facility. Models include Core Based Statistical Area (CBSA) and year fixed 
effects. These estimates are weighted by CSBA population. Standard errors in parenthesis are adjusted for clustering at the CSBA level. 
* p<0.10, ** p<0.05, *** p<0.01 
72 
 
 
Table 7       
Comparing Florida to the Rest of the U.S.   
  
Substance 
Abuse 
Facilities 
SA Facilities 
Accepting 
Medicaid 
Facilities 
Providing 
Some MAT 
Facilities 
Providing 
MAT and 
Accepting 
Medicaid 
Facilities 
Providing Two or 
More Forms of 
MAT 
Facilities 
Providing Two 
plus forms MAT 
and Accepting 
Medicaid 
Panel A: Florida 0.0162** 0.0260* 0.0281*** 0.0511 0.0260*** 0.0960* 
 (0.00737) (0.0153) (0.00920) (0.0348) (0.00741) (0.0526) 
N 737 737 737 737 737 737 
Mean 8.28 8.28 8.28 8.28 8.28 8.28 
 
      
Panel B: Rest of U.S. -0.00157** -0.000350 -0.00231 -0.00892*** -0.00112 -0.00958** 
 (0.000749) (0.00143) (0.00261) (0.00342) (0.00113) (0.00413) 
N 33,197 33,197 33,197 33,197 33,197 33,197 
Mean 7.52 7.52 7.52 7.52 7.52 7.52 
Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per 100,000. Controls include the fraction 
of the county population that are: white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and 
log per capita income. Models include county FE and year FE. Treatment facilities are a count variable: number in a county by 
year. These estimates are weighted by county population. Standard errors in parenthesis are adjusted for clustering at the county 
level. * p<0.10, ** p<0.05, *** p<0.01 
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Figure 1: All Substance Abuse Facility Openings (2005-2016)
 
Notes: Data - SAMHSA N-SSATS Directories 2005-2016  
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Figure 2: Substance Abuse Facilities offering Some MAT Openings (2005-2016) 
 
Notes: Data - SAMHSA N-SSATS Directories 2005-2016  
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Figure 3: Substance Abuse Facilities accepting Medicaid Openings (2005-2016) 
 
Notes: Data - SAMHSA N-SSATS Directories 2005-2016  
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Figure 4: Treatment Facilities by Type and Opioid Death Rate per 100,000 
 
Notes: All SA Facilities refers to the any facility offering substance abuse treatment. Some MAT 
refers to the number of treatment facilities offering any of the three forms of medication assisted 
treatment: methadone, buprenorphine, and/or naltrexone. Opioid death rate on left vertical axis 
and number of treatment facilities on right vertical axis. 
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Figure 5: Coefficient Plot 
 
Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate 
per 100,000. Plot of coefficient estimate and 95% confidence interval. Controls include the 
fraction of the county population that are white, black, female, ages 0-15, ages 16-34 and ages 
35-64 years old, the unemployment rate and the natural log of per capita income. Treatment 
facilities are a count variable per county per year by type of facility. Models include county, year 
and state by year fixed effects. These estimates are weighted by county population. Standard 
errors in parenthesis are adjusted for clustering at the county level. 
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Figure 6: Event Study – Impact of substance abuse facility opening 
Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate 
per 100,000. Event study of counties with no substance abuse treatment facility with one or more 
opening throughout 2005-2016. Controls include the fraction of the county population that are 
white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and 
the natural log of per capita income. Models include county, year and state by year fixed effects. 
These estimates are weighted by county population. Standard errors in parenthesis are adjusted 
for clustering at the county level. 
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Figure 7: Event Study – Impact of substance abuse facility accepting Medicaid 
opening 
 
Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate 
per 100,000. Event study of counties with no substance abuse treatment facility accepting 
Medicaid with one or more opening throughout 2005-2016. Controls include the fraction of the 
county population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, 
the unemployment rate and the natural log of per capita income. Models include county, year and 
state by year fixed effects. These estimates are weighted by county population. Standard errors in 
parenthesis are adjusted for clustering at the county level. 
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Figure 8: Event Study – Impact of substance abuse facility offering some MAT  
 
Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate 
per 100,000. Event study of counties with no substance abuse treatment facility offering MAT 
with one or more opening throughout 2005-2016.  Controls include the fraction of the county 
population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the 
unemployment rate and the natural log of per capita income. Models include county, year and 
state by year fixed effects. These estimates are weighted by county population. Standard errors in 
parenthesis are adjusted for clustering at the county level. 
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Figure 9: Event Study – Impact of substance abuse facility offering some MAT and 
accepting Medicaid opening 
 
Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate 
per 100,000. Event study of counties with a single opening of a treatment facility offering MAT 
and accepting Medicaid throughout 2005-2016.  Controls include the fraction of the county 
population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the 
unemployment rate and the natural log of per capita income. Models include county, year and 
state by year fixed effects. These estimates are weighted by county population. Standard errors in 
parenthesis are adjusted for clustering at the county level. 
  
82 
 
Figure 10: Event Study – Impact of substance abuse facility offering Two plus 
forms of MAT opening 
 
Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate 
per 100,000. Event study of counties with a single opening of a treatment facility offering two 
plus forms of MAT throughout 2005-2016.  Controls include the fraction of the county 
population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the 
unemployment rate and the natural log of per capita income. Models include county, year and 
state by year fixed effects. These estimates are weighted by county population. Standard errors in 
parenthesis are adjusted for clustering at the county level. 
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Figure 11: Event Study – Impact of substance abuse facility offering Two plus 
forms of MAT opening 
 
Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate 
per 100,000. Event study of counties with no substance abuse treatment facility offering two plus 
forms of MAT with one or more opening throughout 2005-2016. Controls include the fraction of 
the county population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years 
old, the unemployment rate and the natural log of per capita income. Models include county, 
year and state by year fixed effects. These estimates are weighted by county population. Standard 
errors in parenthesis are adjusted for clustering at the county level. 
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Figure 12: Annual Admissions by Primary Substance Use 2006-2016 
 
Notes: Data - SAMHSA TEDs Admissions 2006-2016  
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Chapter 3. The Introduction of Abuse-Deterrent Opioids and Rates of Viral 
Infection 
1. Introduction 
 The opioid epidemic has elicited responses from pharmaceutical companies, the Food and 
Drug Administration (FDA) and from federal, state and local governments. Many responses to 
the opioid epidemic have focused on the supply of prescription opioids. The FDA is encouraging 
pharmaceutical companies to develop abuse-deterrent versions of opioid analgesics (FDA, 
2018a). Recent studies (Alpert et al., 2018; Evans et al., 2019; Powell et al., 2019) have 
documented how the introduction of abuse-deterrent OxyContin led to substitution among opioid 
users from prescription opioids to illicit heroin. Beyond the immediate risk of overdose, misuse 
of opioids may be contributing to increases in rates of viral infection through injection drug use 
(IDU). I build on these recent studies by exploring other unintended consequences of the 
reformation of prescription opioids. The creation of abuse-deterrent prescription opioids may 
increase the likelihood that those with opioid use disorder engage in IDU through substitution 
(for example illicit heroin) or through IDU of abuse-deterrent prescription opioids. In this study, 
I find that states that had higher prevalence of OxyContin misuse prior to the introduction of 
abuse-deterrent OxyContin have experienced increases in the rate of acute hepatitis B virus 
(HBV) infection. These states may also be experiencing higher rates of HIV infection though this 
analysis faces data limitations. 
2. Background  
From 1997-2017, there were almost 400,000 overdose deaths involving opioids (CDC, 
2018d). The Council of Economic Advisors estimated that the economic cost of the opioid 
epidemic in 2015 was $504 billion (The Council of Economic Advisors, 2017). These measures 
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may be missing the extent to which the opioid epidemic is impacting rates of viral infection 
including hepatitis and HIV. In 2015, almost 20,000 deaths were attributed to the hepatitis C 
virus (HCV) (Powell et al., 2019). In 2016, there were almost 16,000 deaths among those 
diagnosed with HIV (though these deaths may be due to any cause and may not be attributed to 
HIV) (CDC, 2019). About 1,700 deaths were attributed to HBV in 2016 though this is an 
underestimate of the true number (CDC, 2018a). The treatment cost over a lifetime associated 
with one additional HIV infection is about $380,000 (CDC, 2017) and $205,000 associated with 
one additional case of chronic HCV (Razavi et al., 2013). Given these facts, it is important to 
understand how the epidemic of drug use in the U.S. has impacted new viral infections. This 
understanding could inform policy and prevention efforts going forward.   
2.1 Viral Hepatitis 
Both HBV and HCV can become chronic infections which remain significant public 
health problems throughout the U.S. HCV is responsible for more deaths in the U.S. than any 
other infectious disease (Powell et al., 2019). Approximately 75-85% of those infected with 
HCV develop chronic HCV while HBV is much more likely to develop into a chronic infection 
among infants and children (CDC, 2016). About 5% of infected adults will develop chronic 
HBV, 30-50% of children will develop chronic HBV and 90% of infants who receive HBV from 
their mother will develop chronic HBV (CDC, 2016). An estimated 850,000 Americans have 
chronic HBV (CDC, 2018a). Chronic HBV can lead to liver damage, liver cancer and death. 
From 1999-2005, rates of HCV and HBV infections decreased significantly (figure 1). Rates of 
HCV infection began to increase in 2005 while rates of HBV infection began to level off around 
2008-2009. 
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HBV is a viral infection which can be contracted when infected blood, semen, or other 
bodily fluid enters the body (CDC, 2018a). Rates of acute HBV declined steadily throughout the 
1990’s with the introduction and dissemination of the hepatitis B vaccine (CDC, 2019). As of 
2016, about 71% of newborns in the U.S. received the hepatitis B vaccine within the first 3 days 
of birth (CDC, 2018c). In the same year, the hepatitis B vaccine covered about 1 out of 4 adults 
(CDC, 2018e). The Centers for Disease Control and Prevention (CDC) estimates that there were 
20,900 new cases of HBV in 2016 (CDC, 2016). Many people infected with HBV are not aware 
that they are infected with the virus (CDC, 2018a).  
The population in the U.S. with an opioid use disorder (OUD) is estimated to be to 2.1 
million (HHS, 2019). About 886,000 of those are heroin users (HHS, 2019). The increasing 
prevalence of OUD has increased the size of the population engaging in IDU. Among the many 
risks facing those who engage in IDU is the contraction of a viral disease. The CDC estimates 
that from 2003 to 2010 there were approximately 3.5 million new cases of HCV (CDC, 2016). 
From 2010-2016, there was a 3.5-fold increase in cases of HCV reported to the CDC (most cases 
go unreported) (CDC, 2016). About 60% of new HCV cases are related to IDU (NASTAD, 
2018). Many opioid users whose first opioid use came in the form of a prescription pill go on to 
use opioids via injection. An estimated 10-20% who misuse prescription opioids will go on to 
use prescription opioids or heroin via injection (Van Handel et al., 2016). 
The opioid epidemic has been linked to new cases of viral hepatitis. Most new cases of 
HBV and HCV have occurred among people who engage in IDU (CDC, 2018d). Zibbell et al. 
(2017) examine the Substance Abuse and Mental Health Services Administration’s Treatment 
Episode Data Set. The authors find that between 2004 and 2014, admission to treatment for 
substance use disorder (SUD) attributed to IDU increased by 76% (Zibbell et al., 2017). 
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Suryaprasad et al. (2014) examine follow up interviews conducted with young persons recently 
infected with HCV in 2011 and 2012.  Among those interviewed, 84% reported ever using drugs 
and/or alcohol recreationally (Suryaprasad et al., 2014). Among that subgroup, 74% reported 
using OxyContin or oxycodone and 61% reported using heroin (Suryaprasad et al., 2014). Of 
those who reported using both heroin and prescription opioids, heroin use started about 2 and a 
half years after the first use of prescription opioids (Suryaprasad et al., 2014). Zibbell et al. 
(2017) find that the increasing incidence of HCV from 2004 to 2014 mirrored increases in 
admission to SUD treatment attributed to injection use of heroin and prescription opioid 
analgesics.  
Public policy intended to curb the opioid epidemic has often targeted the supply of 
opioids. The literature examining these supply side policies has increasingly shown the 
unintended consequences including causing those with OUD to seek substitutes for prescription 
opioid analgesics. Cicero et al. (2014) analyze survey data of patients entering substance abuse 
treatment for heroin dependence and found that 94% of respondents indicated that they used 
heroin because prescription opioid analgesics were becoming too difficult or too expensive to 
obtain. Further, about half of respondents indicated that if there were no limiting factors, they 
would prefer prescription opioid analgesics over heroin (Cicero et al., 2014).  
Among the efforts focused on the supply of prescription opioids is the development of 
abuse-deterrent formulations of prescription opioids which has been encouraged by the FDA 
(FDA, 2018a). Abuse-deterrent formulations generally seek to target known forms of abuse like 
crushing and snorting or dissolving and injecting (FDA, 2018a). OxyContin has been one of the 
most widely misused prescription opioids (Cicero et al., 2005). OxyContin sales exceeded $3 
billion in 2010 (Alpert et al., 2018). The introduction of abuse-deterrent OxyContin in 2010 led 
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to a decrease in the distribution of OxyContin and a decrease in the misuse of OxyContin (Alpert 
et al., 2018). 
However, the introduction of abuse-deterrent OxyContin also led to substitution across 
opioid types among opioid users. This substitution was particularly problematic in states with 
higher rates of OxyContin misuse prior to reformulation. Powell et al. (2019) show that the 
introduction of abuse-deterrent OxyContin had the additional consequence of increasing rates of 
HCV. States with rates of OxyContin misuse above the median experienced 222% growth in 
rates of HCV while states below the median experienced 75% growth in rates of HCV (Powell et 
al., 2019). In states that received oxycodone (the active ingredient in OxyContin) shipments per 
capita above the median, the monthly heroin related death rate per 100,000 increased from about 
0.1 to 0.4 by 2014 (Evans et al., 2019). In states below the median, the monthly heroin related 
death rate also increased but did not exceed 0.25 by 2014 (Evans et al., 2019). Alpert et al. 
(2018) find that a one percentage point increase in OxyContin misuse prior to reformulation led 
to an increase of 2.5 additional heroin deaths per 100,000. Prior to reformulation, OxyContin was 
typically misused by crushing the pills which enabled chewing, snorting or injecting them 
(Alpert et al. 2018). To the extent that the reformulation of OxyContin led users to substitution 
across opioid types, the reformulation of OxyContin may have led to more IDU.  
2.2 HIV 
While new HIV diagnoses have declined nationally, new cases have been linked to IDU. 
According to the CDC: “About 1 in 10 new HIV diagnoses in the United States are attributed to 
injection drug use or male-to-male sexual contact and injection drug use” (CDC, 2018b). 2015 
was the first year in over two decades in which the number of HIV diagnoses attributed to IDU 
increased (Dawson and Kates, 2018). Among those who engage in IDU, comorbidity rates 
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between HIV and HCV are high. Of those with HIV who engage in IDU, about 80% also have 
HCV (NASTAD, 2018). Chronic pain is more prominent among those infected with HIV 
(Cunningham, 2018). Estimates suggest that about 21% to 53% of individuals with HIV are 
prescribed opioids and that patients with HIV are prescribed opioids in higher doses 
(Cunningham, 2018).  Compared to the general population, those infected with HIV are more 
likely to have a SUD (Cunningham, 2018). 
Opana ER was a high strength prescription opioid produced by Endo Pharmaceuticals. 
Similar to OxyContin, Endo Pharmaceuticals replaced Opana ER with an abuse-deterrent 
formula in 2012. Here is a description of the properties of the abuse-deterrent product from the 
FDA: “The product, currently marketed by Endo Pharmaceuticals, is a reformulation of the 
original product, designed with physicochemical properties intended to make the drug resistant 
to physical and chemical manipulation for abuse by snorting and injecting“ (FDA, 2018b). Peters 
et al. (2016) identified 181 diagnosed cases of HIV infection in Indiana from 2014-2015. About 
88 percent of these patients reported IDU of extended release Oxymorphone (Opana ER) (Peters 
et al., 2016). In June of 2017, the FDA requested Endo Pharmaceuticals remove Opana ER from 
the marketplace (FDA, 2017). 
Figure 9 shows the HIV diagnoses rate in the state of Indiana. In the years following the 
release of abuse-deterrent Opana, Indiana experienced a massive spike in HIV diagnoses. 
Interviews conducted in Austin, IN, the town at the center of the HIV outbreak, revealed how the 
reformulation of Opana ER may have played a role. Prior to reformulation, Opana was misused 
by crushing pills and then snorting, bypassing the prescription’s time release (Herald, 2016). 
When the abuse-deterrent version was introduced, these users switched from crushing and 
snorting Opana to cooking the prescription for injection use (Herald, 2016). These interviews 
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suggest that the release of abuse-deterrent Opana had the unintended consequence of leading to 
increased IDU which increased the potential spread of viral disease. While the release of abuse-
deterrent OxyContin had nationwide repercussions, misuse of Opana was much less widespread 
prior to reformulation. Oxycodone is the active ingratiate in OxyContin while oxymorphone is 
the active ingredient in Opana. In 2008, about 250 grams of oxymorphone were distributed in the 
U.S. per 100,000 people compared to about 12,450 grams of oxycodone per 100,000 people 
(DEA ARCOS, 2008). 
3. Data  
Data regarding rates of HIV and viral hepatitis infection come from the Centers for 
Disease Control and National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention 
(NCHHSTP). The NCHHSTP data contain the infection rate per 100,000 at the state year level 
including: HIV, HBV and HCV. The explanatory variable of interest measures the amount of 
nonmedical use of OxyContin by state prior to the reformulation of OxyContin. These data were 
obtained from Alpert et al., (2018). The authors constructed the measure using data from the 
National Survey on Drug Use and Health. As a secondary measure, misuse of OxyContin is 
measured using shipments of prescription opioid analgesics. These data come from the Drug 
Enforcement Agency (DEA) Automation of Reports and Consolidated Orders System (ARCOS) 
Retail Drug Summary Reports.  
A set of control variables used in the study include demographic data, economic data and 
data regarding changes in state policy. Population and demographic data come from the National 
Center for Health Statistics (NCHS) Bridged-Race Population Estimates. The demographic 
controls include the share of the state population that are ages 0-15, ages 16-35, ages 36-64, 
female, white and black. Data regarding the unemployment rate comes from the Bureau of Labor 
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Statistics (BLS) Local Area Unemployment Statistics (LAUS). The implementation dates of 
Prescription Drug Monitoring Programs (PDMP) were obtained from Kilby (2015) and the 
National Alliance for Model State Drug Laws (2018). Effective dates of PDMPs with physician 
mandates come from Buchmueller and Carey (2018). Effective dates of state Pain Clinic Laws 
were obtained from Meinhofer and Witman (2018). 
4. Identification Strategy 
The identification strategy used in this study was developed by Alpert et al. (2018). This 
model exploits variation in the prevalence of OxyContin misuse at the state level prior to the 
reformulation of OxyContin. First, the following event study model is estimated: 
𝑌𝑠,𝑡 =  𝛼 +  𝛽 ∗ 𝜌𝑇 ∗ 𝑂𝑥𝑦𝑅𝑎𝑡𝑒𝑠
𝑃𝑟𝑒 + 𝑋𝑠,𝑡
′  𝛾 + 𝛿𝑆  +  𝜆𝑇 + 𝜖𝑠,𝑡       (1) 
Where 𝑌𝑠,𝑡 is the rate of viral infection per 100,000 in state s in year t. 𝑂𝑥𝑦𝑅𝑎𝑡𝑒𝑠
𝑃𝑟𝑒 is the rate of 
OxyContin misuse in state s prior to the reformulation of OxyContin. This measure is interacted 
with a set of year dummies. 𝑋𝑠,𝑡
′  is a vector of control variables including state level demographic 
information, the state unemployment rate and changes in state law relating to the opioid 
epidemic. 𝛿𝑆 represents the state fixed effects and 𝜆𝑇 represents the year fixed effects. 
Next, I estimate the following trend break model following Alpert et al. (2018): 
𝑌𝑠,𝑡 = 𝛼 + 𝛽1[𝑃𝑜𝑠𝑡𝑡 ∗ 𝑂𝑥𝑦𝑅𝑎𝑡𝑒𝑠
𝑃𝑟𝑒] + 𝛽2[𝑡 ∗ 𝑂𝑥𝑦𝑅𝑎𝑡𝑒𝑠
𝑃𝑟𝑒] + 𝛽3[𝑃𝑜𝑠𝑡𝑡
∗ (𝑡 − 2011) ∗ 𝑂𝑥𝑦𝑅𝑎𝑡𝑒𝑠
𝑃𝑟𝑒] + 𝑋𝑠,𝑡
′  𝛾 + 𝛿𝑆  +  𝜖𝑠,𝑡        (2) 
𝑃𝑜𝑠𝑡𝑡 is an indicator variable equal to 1 in the year 2011 and subsequent years and equal to zero 
otherwise, capturing the impact of the reformulation of OxyContin. 𝑡 represents a linear time 
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trend. With respect to estimation of both equations 1 and 2, standard errors are adjusted for 
clustering at the state level. Estimates are weighted by state population. 
5. Results 
Figure 2 is a replication of Exhibit 2 from Powell et al. (2019). This evidence in Powell et 
al. (2019) shows that higher rates of OxyContin misuse prior to reformulation were associated 
with higher rates of HCV infection in the years following reformulation. In figure 3, I apply the 
same empirical strategy and find similar trends with respect to HBV infection rates. There does 
not appear to be any relationship between OxyContin misuse and rates of HBV or HCV infection 
prior to reformulation. However, following reformulation in 2010, states with higher levels of 
OxyContin misuse in the pre-reform period experienced significantly higher growth in the HBV 
infection rate. In figure 4, I consider the HIV infection rate. Unfortunately, the CDC NCHHSTP 
data of HIV diagnoses does not contain records prior to 2008. The 2009 event study coefficient 
estimate is normalized to zero leaving only one year of pre-reform data. In the post reformulation 
years, confidence intervals are large and coefficient estimates are positive. There is insufficient 
evidence in the event study to suggest that states with higher levels of OxyContin misuse prior to 
reformulation experienced higher rates of HIV infection.  
 In figures 5-8, I utilize a secondary measure of OxyContin misuse in the pre-reform 
period. Following Evans et al. (2019), I categorize states that received oxycodone shipments per 
100,000 residents above the median and below the median in 2008 based on DEA ARCOS data. 
In figure 5, it appears that states above and below the median were following similar trends with 
respect to HCV infection rates. Both states above and below the median experience increases in 
HCV infection rates immediately following reformulation. However, states above the median 
continue to experience growth in HCV infection rates from 2013-2016 while the infection rate 
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remains relatively flat in states below the median. In figure 6, it appears that states above and 
below the median were following nearly identical trends in terms of HBV infection rates prior to 
reformulation. While states below the median continued to experience decreasing HBV infection 
rates after the reformulation of OxyContin, states above the median begin experiencing 
increasing HBV infection rates. Using the same classification of states, I plot the population 
weighted mean number of HIV diagnoses. In figure 7, HIV diagnoses from transmission type 
IDU are plotted and in figure 8, HIV diagnoses from transmission type male to male sexual 
contact and IDU are plotted. In both cases, states with oxycodone shipments per 100,000 below 
the median in 2008 have higher mean HIV diagnoses. Following the introduction of abuse-
deterrent OxyContin, the mean number of HIV diagnoses declines more rapidly in states below 
the median than in states above the median. 
In table 2, I estimate the impact of misuse of OxyContin prior to reformulation on rates of 
HBV and HIV. Following Alpert et al. (2018), table 2 reports estimates of 𝛽1 + 2 𝛽3 from 
equation 2 above. In column 3, the estimates suggest that one additional percentage point of 
OxyContin misuse prior to reformulation would lead to 0.376 additional cases of HBV per 
100,000 and 3.27 additional cases of HIV per 100,000. In both cases, the OLS results are not 
precise and the coefficient of interest is not statistically significant. Table 3 presents the results of 
Poisson regression estimation. In the Poisson models, the dependent variable is the number of 
cases of viral infection at the state year level. Results in column 3 suggest that a one percentage 
point increase in OxyContin misuse prior to reform would result in approximately 2 additional 
HBV infections and 1.6 additional HIV infections. For the HBV cases outcome, the coefficient 
of interest is statistically significant at the 1% level in the baseline model but is no longer 
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significant with the inclusion of a full set of controls. For the HIV cases outcome, the results are 
significant at the 1% level in all specifications. 
Finally, I examine the heterogeneity of the effect by transmission type, age, gender and 
race. In table 4, I test each type of HIV transmission. The largest estimated effect size of 
OxyContin misuse prior to reformulation is on HIV diagnoses relating to IDU. The coefficient of 
interest is also statistically significant with respect to HIV diagnoses relating to heterosexual and 
male-to-male sexual contact. In tables 5 and 6, the impact of OxyContin reformulation is largest 
with respect to HIV infections occurring among people between the ages of 25-34, people 
between the ages of 45-54, males and blacks.   
6. Conclusion 
In this study, I build on recent work that has shed light on the large scale, unintended 
consequences of the introduction of abuse-deterrent opioids. These papers (Alpert et al., 2018; 
Evans et al., 2019; Powell et al., 2019) have shown that the reformulation of OxyContin led to 
increases in the heroin related death rate and the HCV infection rate. This study shows that the 
increase in the HCV infection rate in states with higher levels of OxyContin misuse coincided 
with increases in the HBV infection rate. I test the impact of the reformulation of OxyContin on 
rates of HIV infection as well. While these results may be indicative of higher rates of HIV 
infection in states with higher rates OxyContin misuse, the results cannot be validated because of 
insufficient data in the pre-reform period. Results presented in the paper suggest that many 
measures underestimate the true cost of the opioid epidemic. Additional resources many be 
needed to prevent further spread of viral disease related to intravenous use of opioids.  
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8. Tables and Figures 
Figure 1: Rates of Hepatitis 
 
Source: Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral 
Hepatitis, STD, and TB Prevention (NCHHSTP) 
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Figure 2: Hepatitis C Rate Event Study
 
Notes: Replication of Powell et al., (2019) Exhibit 4. The outcome variable is the rate of hepatitis 
C infections per 100,000 at the state year level. Model includes year fixed effects and state fixed 
effects. Controls include age and demographic controls and the unemployment rate and 
Prescription Drug Monitoring Programs, PDMPs with a must access clause, and Pain Clinic 
Laws. Estimates are weighted by the state population. Standard errors are adjusted for clustering 
at the state level. 
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Figure 3: Hepatitis B Rate Event Study 
 
Notes: The outcome variable is the rate of hepatitis B infections per 100,000 at the state year 
level. Model includes year fixed effects and state fixed effects. Controls include age and 
demographic controls and the unemployment rate and Prescription Drug Monitoring Programs, 
PDMPs with a must access clause, and Pain Clinic Laws. Estimates are weighted by the state 
population. Standard errors are adjusted for clustering at the state level. 
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Figure 4: HIV Diagnoses Rate Event Study 
 
Notes: The outcome variable is the rate of HIV diagnoses per 100,000 at the state year level. 
Model includes year fixed effects and state fixed effects. Controls include age and demographic 
controls and the unemployment rate and Prescription Drug Monitoring Programs, PDMPs with a 
must access clause, and Pain Clinic Laws. Estimates are weighted by the state population. 
Standard errors are adjusted for clustering at the state level. 
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Figure 5: Hepatitis C Rate by 2008 Oxycodone Shipments 
 
Notes: Plot of the Hepatitis C rate per 100,000 separating states by Oxycodone shipments 
relative to the median using data from DEA ARCOS and NCHHSTP. Vertical line indicates the 
year in which the abuse-deterrent formula of OxyContin was introduced.   
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Figure 6: Hepatitis B Rate by 2008 Oxycodone Shipments 
 
Notes: Plot of the Hepatitis B rate per 100,000 separating states by Oxycodone shipments 
relative to the median using data from DEA ARCOS and NCHHSTP. Vertical line indicates the 
year in which the abuse-deterrent formula of OxyContin was introduced.   
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Figure 7: HIV Diagnosis by 2008 Oxycodone Shipments, Transmission 
Category IDU 
 
Notes: Plot of the HIV diagnosis within transmission category IDU, separating states by 
Oxycodone shipments relative to the median using data from DEA ARCOS and NCHHSTP. 
Vertical line indicates the year in which the abuse-deterrent formula of OxyContin was 
introduced. 
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Figure 8: HIV Diagnosis by 2008 Oxycodone Shipments, Transmission 
Category Male to Male Sexual Contact and IDU 
 
Notes: Plot of the HIV diagnosis within transmission category male to male sexual contact and 
IDU, separating states by Oxycodone shipments relative to the median using data from DEA 
ARCOS and NCHHSTP. Vertical line indicates the year in which the abuse-deterrent formula of 
OxyContin was introduced.  
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Figure 9: Rate of HIV Diagnoses in Indiana 
 
Notes: Plot of the HIV Diagnoses rate per 100,000 in the state of Indiana. Vertical line indicates 
the year in which the abuse-deterrent formula of Opana ER was introduced.  
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Table 1   
Summary Statistics 
Variable Mean Std. Dev 
Hepatitis B Rate per 100,000 1.73 1.26 
Hepatitis B Cases 219.86 235.65 
Hepatitis C Rate per 100,000 0.42 0.85 
Hepatitis C Cases 47.08 65.03 
HIV Diagnoses Rate per 100,000 16.79 9.95 
HIV Diagnoses Cases 2,120.54 1,905.46 
Initial OxyContin Misuse 0.57 0.22 
Fraction Ages 0-15 0.22 0.02 
Fraction Ages 16-35 0.26 0.01 
Fraction Ages 35-64 0.39 0.02 
Fraction White 0.80 0.09 
Fraction Black 0.13 0.08 
Fraction Female 0.51 0.01 
Prescription Drug Monitoring Programs 0.48 0.50 
Must Access Prescription Drug Monitoring Programs 0.03 0.17 
Pain Clinic Laws 0.07 0.26 
Notes: Data - 1999-2016. Summary statistics are weighted by state population.  
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Table 2  
Impact of OxyContin Reformulation on Viral Disease (OLS) 
  (1) (2) (3) 
Panel A: Hepatitis B    
Initial OxyContin 3-year effect 0.673 0.835 0.376 
 (0.641) (0.712) (0.686) 
Panel B: HIV    
Initial OxyContin 3-year effect 1.658 3.013 3.283 
 (2.825) (2.865) (3.578) 
    
Demographic and Economic 
Covariates 
No Yes Yes 
Controls for State Policy No No Yes 
Notes: Dependent Variable - infection/diagnoses rate per 100,000. Population 
weighted OLS regression estimates. Models include year fixed effect and state 
fixed effect. Standard errors in parentheses are adjusted for clustering at the state 
level. * p<0.10, ** p<0.05, *** p<0.01 
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Table 3 
Impact of OxyContin Reformulation on Viral Disease (Poisson) 
  (1) (2) (3) 
Panel A: Hepatitis B    
Initial OxyContin 3-year effect 1.343*** 1.143 0.717 
 (0.412) (0.386) (0.4878) 
Panel B: HIV    
Initial OxyContin 3-year effect 0.377*** 0.571*** 0.495*** 
 (0.1454) (0.1379) (0.143) 
    
Log Population Control Yes Yes Yes 
Demographic and Economic 
Covariates 
No Yes Yes 
Controls for State Policy No No Yes 
Notes: Dependent Variable - new infections/cases of viral disease. Population 
weighted Poisson regression estimates. Models include year fixed effect and state 
fixed effect. Standard errors in parentheses are adjusted for clustering at the state 
level. * p<0.10, ** p<0.05, *** p<0.01 
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Table 4 
HIV Diagnoses Heterogeneity by Transmission Type 
  
All HIV 
Diagnoses 
IDU 
MM 
Sexual 
Contact 
and IDU 
MM 
Sexual 
Contact 
Heterosexual 
Contact 
Initial OxyContin 3-year 
effect 
0.500*** 0.795** -0.088 0.450** 0.513*** 
 (0.141) (0.310) (0.263) (0.178) (0.177) 
 
     
Log Population Control Yes Yes Yes Yes Yes 
Demographic and Economic 
Covariates 
Yes Yes Yes Yes Yes 
Policy Covariates Yes Yes Yes Yes Yes 
Notes: Dependent Variable - new infections/cases of viral disease. Population weighted Poisson 
regression estimates. Models include year fixed effect and state fixed effect. Standard errors in 
parentheses are adjusted for clustering at the state level. * p<0.10, ** p<0.05, *** p<0.01 
 
 
Table 5 
HIV Diagnoses Heterogeneity by Age Group 
  
Ages 25-34 Ages 35-44 Ages 45-54 
Ages 55 
plus 
Initial OxyContin 3-year effect 5.867 3.967 5.260 2.614 
 (3.885) (8.344) (6.196) (1.688) 
     
Demographic and Economic 
Covariates 
Yes Yes Yes Yes 
Policy Covariates Yes Yes Yes Yes 
Notes: Dependent Variable - infection/diagnoses rate per 100,000. Population weighted OLS 
regression estimates. Models include year fixed effect and state fixed effect. Standard errors in 
parentheses are adjusted for clustering at the state level. * p<0.10, ** p<0.05, *** p<0.01 
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Table 6 
HIV Diagnoses Heterogeneity by Race and Gender 
  Male Female White Black Hispanic 
Initial OxyContin 3-year effect 5.718 1.496 1.515 31.049* 1.615 
 (4.703) (2.696) (1.522) (15.605) (5.609) 
      
Demographic and Economic 
Covariates 
Yes Yes Yes Yes Yes 
Policy Covariates Yes Yes Yes Yes Yes 
Notes: Dependent Variable - infection/diagnoses rate per 100,000. Population weighted OLS regression 
estimates. Models include year fixed effect and state fixed effect. Standard errors in parentheses are 
adjusted for clustering at the state level. * p<0.10, ** p<0.05, *** p<0.01 
 
 
  
114 
 
I. Appendix to Chapter 1 
Table A1: State Law Effective Dates  
State 
PDMP Date of 
Implementation 
"Must 
Access" 
PDMP 
Naloxone 
Access 
Laws 
Good 
Samaritan 
Laws 
Pain Clinic 
Laws 
Medical 
Marijuana 
Laws 
Alabama Apr-2007 
 Jun-2015 Jun-2015 2013  
Alaska Jan-2012  Mar-2016 Oct-2014   
Arizona Dec-2008 
    Apr-2011 
Arkansas Mar-2013 
 Jul-2015 Jul-2015   
California Jan-2009 
 Jan-2008 Jan-2013   
Colorado Feb-2008 
 May-2013 May-2012   
Connecticut Jul-2008 
 Oct-2003 Oct-2011  Oct-2012 
D.C. 
  Mar-2013 Mar-2013  Jul-2010 
Delaware Aug-2012 2012 Aug-2014 Aug-2013 
 Jul-2011 
Florida Oct-2011  Jun-2015 Oct-2012 2010  
Georgia Jul-2013  Apr-2014 Apr-2014 2013  
Hawaii 1996 
 Jun-2016 Jul-2015   
Idaho 1998 
 Jul-2015    
Illinois 1999 
 Jan-2010 Jun-2012  Jan-2014 
Indiana Jan-2007 
 Apr-2015    
Iowa Mar-2009 
 May-2016    
Kansas Apr-2011 
     
Kentucky 1999 2012 Jun-2013 Mar-2015 2012 
 
Louisiana Jan-2009 2008* Aug-2015 Aug-2014 2005 
 
Maine Jan-2005 
 Apr-2014    
Maryland Jan-2014  Oct-2013 Oct-2014  Jun-2014 
Massachusetts Aug-2010 
 Aug-2012 Aug-2012  Jan-2013 
Michigan 1998 
 Oct-2014   Dec-2008 
Minnesota Apr-2010 
 May-2014 Jul-2014  May-2014 
Mississippi Dec-2005 
 Jul-2015 Jul-2015 2012  
Missouri 
      
Montana Oct-2012 
     
Nebraska 
  May-2015    
Nevada 1997 2007 Oct-2015 Oct-2015 
  
New Hampshire   Jun-2015 Sep-2015  Jul-2013 
New Jersey Jan-2012 
 Jul-2013 May-2013  Oct-2010 
New Mexico Aug-2012 2012 Apr-2001 Jun-2007 
 Jul-2007 
New York 1973 2013 Jun-2014 Sep-2011 
 Jul-2014 
North Carolina Oct-2007 
 Apr-2013 Apr-2013   
North Dakota Jan-2007 
 Aug-2015 Aug-2015   
Ohio Oct-2011 2012 Mar-2014 
 2011  
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Oklahoma Jul-2006 2011 Nov-2013 
   
Oregon Sep-2011 
 Jun-2013 Jan-2016   
Pennsylvania 
  Nov-2014 Dec-2014   
Rhode Island 2001 
 Jun-2012 Jun-2012  Jan-2006 
South Carolina Jun-2008 
 Jun-2015    
South Dakota Mar-2012 
 Jul-2016    
Tennessee 1990 2013 Jul-2014 Jul-2015 2012 
 
Texas 1989 
 Sep-2015  2009  
Utah 1997 
 May-2014 Mar-2014   
Vermont Apr-2009 
 Jul-2013 Jun-2013  Jul-2004 
Virginia Jun-2006 
 Jul-2013 Jul-2015   
Washington Jan-2012  Jun-2010 Jun-2010   
West Virginia 1995 2012 May-2015 Jun-2015 2012 
 
Wisconsin May-2013  Apr-2014 Apr-2014   
Wyoming Jan-2004           
Sources: The National Alliance For Model State Drug Laws (2018), Kilby (2015), Buchmueller and Carey (2018), 
Rees et al. (2019), Meinhofer and Witman (2018), Baggio et al. (2018). Notes: This measure of PDMP includes 
earlier substances monitoring programs. Louisiana started receiving prescription data in 2008 and allowed users to 
access PDMP data on Jan 1st 2009. 
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Table A2: Robustness to Definition of Treatment and Control     
  
All Opioids Heroin Other Opioids Methadone Synthetic 
Other 
Narcotics 
(1) Full Sample 0.0682 -0.308*** 0.00212 0.0483 0.107 0.0523 
 (0.0545) (0.107) (0.0809) (0.0620) (0.149) (0.0889) 
N 918 918 918 918 918 918 
 
      
(2) Coding following Meinhofer 0.1000* -0.347** 0.0520 0.146*** -0.00913 0.224* 
and Witman (2018) (0.0569) (0.168) (0.129) (0.0554) (0.192) (0.118) 
N 918 918 918 918 918 918 
 
      
(3) Preferred Specification 0.0789 -0.348*** 0.00457 0.0796 0.121 0.0127 
 (0.0500) (0.122) (0.0816) (0.0604) (0.148) (0.0897) 
N 864 864 864 864 864 864 
       
(4) Preferred Specification 0.0751 -0.320*** 0.00256 0.0816 0.0983 0.0587 
and Drop MA and OR (0.0505) (0.121) (0.0838) (0.0631) (0.151) (0.0943) 
N 810 810 810 810 810 810 
Notes: State year level data: 1999-2016. Population weighted Poisson Regression estimates. Models include year fixed effect 
and state fixed effect. Controls include pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs), age 
and demographic controls and the unemployment rate. Standard errors in parentheses are clustered at the state level. * p<0.10, 
** p<0.05, *** p<0.01 
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Table A3: Methadone Coding Sensitivity Analysis 
  
Poisson 
OLS - Inverse 
Hyperbolic Sine 
OLS - Natural 
Log (Death Rate 
+ 1) 
Number of 
Deaths 
(1) Methadone (T40.3) is listed as condition 1-4 0.310*** 0.133** 0.101** 55,484 
 (0.0878) (0.0589) (0.0454)  
     
(2) Methadone (T40.3) is listed as condition 1 0.277*** 0.117** 0.0894** 36,120 
 (0.0912) (0.0557) (0.0427)  
     
(3) Methadone (T40.3) is listed as condition 1 excluding 0.273*** 0.115** 0.0880** 35,327 
Other Synthetic Narcotics (T40.4) is listed as condition 2-9 (0.0907) (0.0552) (0.0423)  
     
(4) Methadone (T40.3) is listed as condition 1 excluding 0.262*** 0.113** 0.0867** 31,799 
Other Opioids (T40.2) is listed as condition 2-9 (0.0907) (0.0562) (0.0430)  
     
(5) Methadone (T40.3) is listed as condition 1 excluding  0.275*** 0.116** 0.0889** 35,892 
Heroin (T40.1) is listed as condition 2-9 (0.0911) (0.0556) (0.0426)  
     
(6) Methadone (T40.3) is listed as condition 1 excluding  0.272*** 0.117** 0.0894** 35,645 
Other/Unspecified Narcotics (T40.6) is listed as condition 2-9 (0.0924) (0.0554) (0.0425)  
     
(7) Methadone (T40.3) is listed as condition 1, excluding  0.248*** 0.110* 0.0846* 30,634 
any other opioid (ICD-10 code T40.1, T40.2, T40.4, T40.6) (0.0911) (0.0551) (0.0421)  
is listed as condition 2-6     
 
    
N 41,853 41,853 41,853  
Notes: County year level data: 2003-2016. Population weighted regression estimates. Models include year fixed effect and state fixed 
effect. Expanding states with previous expansion have been dropped from the sample (DC, MN, NJ and WA). Controls include pertinent 
laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs), age and demographic controls and the unemployment rate. 
Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01 
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Table A4: Drop Northeast       
  
All Opioids Heroin 
Other 
Opioids 
Methadone Synthetic 
Other 
Narcotics 
Drop New England 0.00211 -0.264* -0.00146 0.231** 0.202 0.0154 
 (0.0665) (0.139) (0.0737) (0.0998) (0.236) (0.0859) 
N 42,987 42,987 42,987 42,987 42,987 42,987 
       
Drop New England, -0.0476 -0.302* -0.00469 0.298*** -0.000921 -0.0264 
NY, PA, OH and MD (0.0673) (0.170) (0.0713) (0.107) (0.215) (0.0800) 
N 39,613 39,613 39,613 39,613 39,613 39,613 
Notes: County year level data: 2003-2016. Population weighted Poisson regression estimates. Models include year 
fixed effect and state fixed effect. Controls include pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs, 
MMLs and PCLs), age and demographic controls and the unemployment rate. Standard errors in parentheses are 
clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01 
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Table A5: State and County Level Results - Same Sample Window    
  
All Opioids Heroin Other Opioids Methadone Synthetic 
Other 
Narcotics 
State Level Data       
Baseline 0.0612 -0.244** 0.00214 0.0211 0.296** 0.0233 
 (0.0483) (0.120) (0.0785) (0.0462) (0.130) (0.137) 
 
      
Controls for Pertinent Laws 0.0315 -0.300*** -0.0236 -0.0168 0.179 0.0376 
 (0.0449) (0.113) (0.0689) (0.0536) (0.144) (0.0776) 
 
      
Control for Fentanyl Seizures -0.0117 -0.296** -0.0265 -0.0211 0.0944 -0.0345 
 (0.0451) (0.118) (0.0701) (0.0585) (0.140) (0.0697) 
Mean of Dependent 920.28 228.65 410.35 163.13 162.03 108.67 
N 658 658 658 658 658 658 
County Level Data       
Baseline 0.0741 -0.0338 0.0609 0.400*** 0.425 -0.314 
 (0.0780) (0.233) (0.117) (0.0892) (0.291) (0.250) 
       
Controls for Pertinent Laws 0.0184 -0.247* 0.00187 0.310*** 0.230 -0.116 
 (0.0664) (0.127) (0.0718) (0.0878) (0.227) (0.103) 
       
Control for Fentanyl Seizures 0.0165 -0.250* 0.000310 0.316*** 0.233 -0.119 
 (0.0659) (0.128) (0.0721) (0.0882) (0.226) (0.104) 
       
Mean of Dependent 70.39 21.79 28.95 9.65 11.23 11.35 
N 41,853 41,853 41,853 41,853 41,853 41,853 
Notes: Data: 2003-2016. Population weighted Poisson regression estimates. Models include year fixed effect and state 
fixed effect. Expanding states with previous expansion have been dropped from the sample (DC, MN, NJ and WA). 
Controls include the natural log of the state population, age and demographic controls and the unemployment rate. 
Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01 
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Table A6: Impact of Medicaid Expansions on Heroin Deaths - Drop Each Individual Treatment State 
    Early Expanding States 2014 Expanding States 
State  
Dropped 
50 States 
+ D.C. 
CA CT D.C. MN NJ WA AZ AR CO DE 
 
-0.302*** -0.196 -0.296*** -0.303*** -0.302*** -0.329*** -0.307*** -0.331*** -0.302*** -0.307*** -0.302*** 
 
(0.106) (0.134) (0.107) (0.107) (0.107) (0.116) (0.107) (0.107) (0.106) (0.107) (0.106) 
 
           
N 918 900 900 900 900 900 900 900 900 900 900 
 
           
  2014 Expanding States 
State  HI IL IA KY MD MA MI NV NH NM NY 
Dropped -0.301*** -0.321*** -0.303*** -0.303*** -0.302*** -0.293*** -0.361*** -0.302*** -0.301*** -0.303*** -0.197** 
 
(0.106) (0.109) (0.106) (0.107) (0.108) (0.108) (0.0910) (0.106) (0.106) (0.106) (0.0886) 
 
           
N 900 900 900 900 900 900 900 900 900 900 900 
  2014 Expanding States Late Expanding States 
State  ND OH OR RI VT WV AK IN MT LA PA 
Dropped -0.302*** -0.295** -0.295*** -0.301*** -0.302*** -0.300*** -0.302*** -0.312*** -0.302*** -0.303*** -0.261** 
 
(0.106) (0.120) (0.105) (0.106) (0.106) (0.106) (0.106) (0.105) (0.106) (0.107) (0.114) 
 
           
N 900 900 900 900 900 900 900 900 900 900 900 
Notes: Dependent variable: Heroin deaths. State year level data: 1999-2016. Population weighted Poisson regression estimates. Models include year fixed 
effect and state fixed effect. Controls include pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs), age and demographic controls 
and the unemployment rate. Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01 
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Table A7: Robustness to Functional Form - Negative Binomial 
  
All Opioids Heroin Other Opioids Methadone Synthetic 
Other 
Narcotics 
Baseline 0.0883 -0.346** -0.0495 0.192** 0.113 0.0241 
 (0.0560) (0.163) (0.129) (0.0746) (0.114) (0.124) 
       
Controls for Pertinent Laws 0.0616 -0.399*** -0.0853 0.156*** 0.0263 0.0158 
 (0.0561) (0.143) (0.113) (0.0549) (0.128) (0.105) 
       
Controls for Fentanyl Seizures 0.0226 -0.402*** -0.0835 0.161*** -0.0694 -0.0233 
 (0.0527) (0.148) (0.114) (0.0571) (0.122) (0.103) 
       
Mean of Dependent 819.74 201.86 362.43 140.14 136.49 112.89 
N 846 846 846 846 846 846 
Notes: State year level data: 1999-2016. Population weighted Negative Binomial regression estimates. Models include 
year fixed effect and state fixed effect. Expanding states with previous expansion have been dropped from the sample 
(DC, MN, NJ and WA). Controls include the natural log of the state population, age and demographic controls and the 
unemployment rate. Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01 
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Table A8: Robustness to Estimation of Unweighted Poisson 
  
All Opioids Heroin Other Opioids Methadone Synthetic 
Other 
Narcotics 
Baseline 0.0828 -0.217* -0.0397 0.129* 0.220 0.0309 
 (0.0656) (0.132) (0.0786) (0.0664) (0.160) (0.157) 
       
Controls for Pertinent Laws 0.0433 -0.306*** -0.0720 0.100* 0.0879 0.0110 
 (0.0680) (0.111) (0.0795) (0.0570) (0.165) (0.103) 
       
Controls for Fentanyl Seizures -0.00609 -0.308*** -0.0797 0.105* -0.0142 -0.0545 
 (0.0612) (0.117) (0.0815) (0.0587) (0.150) (0.106) 
       
Mean of Dependent 819.74 201.86 362.43 140.14 136.49 112.89 
N 846 846 846 846 846 846 
Notes: State year level data: 1999-2016. Poisson regression estimates. Models include year fixed effect and state fixed effect. 
Expanding states with previous expansion have been dropped from the sample (DC, MN, NJ and WA). Controls include the 
natural log of the state population, age and demographic controls and the unemployment rate. Standard errors in parentheses are 
clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01 
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Table A9: Inclusion of ICD-10 Code: T50.9   
  
All Opioids 
All Opioids & 
T50.9 
Poisson   
Medicaid Expansion 0.0778 0.0546 
 (0.0489) (0.0360) 
   
OLS - Inverse Hyperbolic Sine (Death Rate) 0.0939 0.0719 
Medicaid Expansion (0.0838) (0.0656) 
   
Natural Log (Death Rate + 1) 0.101 0.0721 
Medicaid Expansion (0.0852) (0.0661) 
   
N 846 846 
Notes: State year level data: 1999-2016. Population weighted regression 
estimates. Models include year fixed effect and state fixed effect. Controls include 
pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs), 
age and demographic controls and the unemployment rate. Standard errors in 
parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01 
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II. Appendix to Chapter 2 
Table A1       
Robustness   
  
Substance 
Abuse 
Facilities 
SA Facilities 
Accepting 
Medicaid 
Facilities 
Providing 
Some MAT 
Facilities 
Providing 
MAT and 
Accepting 
Medicaid 
Facilities 
Providing Two 
or More Forms 
of MAT 
Facilities 
Providing Two 
plus forms MAT 
and Accepting 
Medicaid 
Panel A: Weighted OLS -0.00117* -0.0000921 -0.00154 -0.00661** -0.000844 -0.00748** 
Dependent LN(Death Rate + 1) (0.000632) (0.00124) (0.00205) (0.00284) (0.000912) (0.00344) 
N 33,197 33,197 33,197 33,197 33,197 33,197 
Mean 7.52 7.52 7.52 7.52 7.52 7.52 
 
      
Panel B: Unweighted OLS 0.00192 0.00178 -0.00379 -0.00741 -0.00162 -0.0122** 
Dependent IHS(Death Rate) (0.00257) (0.00336) (0.00359) (0.00501) (0.00203) (0.00587) 
N 33,197 33,197 33,197 33,197 33,197 33,197 
Mean 7.52 7.52 7.52 7.52 7.52 7.52 
 
      
Panel C: Weighted Poisson -0.00141** -0.00103 0.00165 -0.00190 0.000241 -0.00452 
Dependent Deaths (0.000560) (0.000892) (0.00168) (0.00238) (0.000654) (0.00349) 
N 30,276 30,276 30,276 30,276 30,276 30,276 
Mean 71.59 71.59 71.59 71.59 71.59 71.59 
Notes: Controls include the fraction of the county population that are: white, black, female, ages 0-15, ages 16-34 and ages 35-64 years 
old, the unemployment rate and per capita income. Models include county FE, year FE and state by year FE. Treatment facilities are a 
count variable: number in a county by year. These estimates are weighted by county population. Standard errors in parenthesis are 
adjusted for clustering at the county level. * p<0.10, ** p<0.05, *** p<0.01 
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Table A2       
Heterogeneity by Gender   
  
Substance 
Abuse Facilities 
SA Facilities 
Accepting 
Medicaid 
Facilities 
Providing 
Some MAT 
Facilities 
Providing 
MAT and 
Accepting 
Medicaid 
Facilities 
Providing Two or 
More Forms of 
MAT 
Facilities 
Providing Two 
plus forms MAT 
and Accepting 
Medicaid 
Panel A: Male -0.00161** -0.000336 -0.00369 -0.0112*** -0.00160 -0.0117*** 
 (0.000761) (0.00159) (0.00281) (0.00379) (0.00120) (0.00415) 
Mean 10.09 10.09 10.09 10.09 10.09 10.09 
 
      
Panel B: Female -0.00131 -0.000550 -0.0000794 -0.00543 -0.000351 -0.00818* 
 (0.00104) (0.00166) (0.00258) (0.00341) (0.00125) (0.00470) 
Mean 5.15 5.15 5.15 5.15 5.15 5.15 
N 33,197 33,197 33,197 33,197 33,197 33,197 
Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per 100,000. Controls include the fraction of 
the county population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and per 
capita income. Models include county FE, year FE and state by year FE. Treatment facilities are a count variable: number in a county by 
year. These estimates are weighted by county population. Standard errors in parenthesis are adjusted for clustering at the county level. * 
p<0.10, ** p<0.05, *** p<0.01 
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Table A3       
Heterogeneity by Race   
  
Substance 
Abuse Facilities 
SA Facilities 
Accepting 
Medicaid 
Facilities 
Providing 
Some MAT 
Facilities 
Providing 
MAT and 
Accepting 
Medicaid 
Facilities 
Providing Two or 
More Forms of 
MAT 
Facilities 
Providing Two 
plus forms MAT 
and Accepting 
Medicaid 
Panel A: White -0.00184** -0.000502 -0.00217 -0.00795** -0.00152 -0.00893** 
 (0.000781) (0.00153) (0.00259) (0.00357) (0.00114) (0.00406) 
N 33,197 33,197 33,197 33,197 33,197 33,197 
Mean 8.75 8.75 8.75 8.75 8.75 8.75 
       
Panel B: Black 0.000425 -0.00127 0.000494 -0.00314 0.00176 -0.00500 
 (0.00144) (0.00223) (0.00310) (0.00487) (0.00156) (0.00573) 
N 33,142 33,142 33,142 33,142 33,142 33,142 
Mean 4.62 4.62 4.62 4.62 4.62 4.62 
       
Panel C: Hispanic 0.000862 -0.000527 -0.00189 -0.00437 -0.000142 -0.00226 
 (0.000926) (0.00163) (0.00135) (0.00282) (0.00127) (0.00324) 
N 31,973 31,973 31,973 31,973 31,973 31,973 
Mean 3.86 3.86 3.86 3.86 3.86 3.86 
Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per 100,000. Controls include the fraction of 
the county population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and per 
capita income. Models include county FE, year FE and state by year FE. Treatment facilities are a count variable: number in a county 
by year. These estimates are weighted by county population. Standard errors in parenthesis are adjusted for clustering at the county 
level. * p<0.10, ** p<0.05, *** p<0.01 
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Table A4       
Heterogeneity by County Population   
  
Substance 
Abuse Facilities 
SA Facilities 
Accepting 
Medicaid 
Facilities 
Providing 
Some MAT 
Facilities 
Providing 
MAT and 
Accepting 
Medicaid 
Facilities 
Providing Two or 
More Forms of 
MAT 
Facilities 
Providing Two 
plus forms MAT 
and Accepting 
Medicaid 
Panel A: Urban -0.00163* -0.00116 -0.000795 -0.00640 -0.000922 -0.00591 
 (0.000844) (0.00150) (0.00295) (0.00405) (0.00119) (0.00552) 
N 2,493 2,493 2,493 2,493 2,493 2,493 
Mean 7.86 7.86 7.86 7.86 7.86 7.86 
 
      
Panel B: Medium 0.00641 0.00539 -0.00398 -0.00812 0.00517 0.00726 
 (0.00651) (0.00788) (0.0107) (0.0127) (0.00793) (0.0193) 
N 7,432 7,432 7,432 7,432 7,432 7,432 
Mean 7.4 7.4 7.4 7.4 7.4 7.4 
 
      
Panel C: Rural 0.00139 -0.0185 -0.00355 -0.00884 -0.0130 -0.0133 
 (0.0158) (0.0165) (0.0284) (0.0319) (0.0317) (0.0612) 
N 23,126 23,126 23,126 23,126 23,126 23,126 
Mean 6.22 6.22 6.22 6.22 6.22 6.22 
Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per 100,000. Urban counties defined as 
counties with mean population greater than or equal to 250,000. Rural counties defined as counties with mean population less than or 
equal to 50,000. Controls include the fraction of the county population that are: white, black, female, ages 0-15, ages 16-34 and ages 
35-64 years old, the unemployment rate and per capita income. Models include county FE, year FE and state by year FE. Treatment 
facilities are a count variable: number in a county by year. These estimates are weighted by county population. Standard errors in 
parenthesis are adjusted for clustering at the county level. * p<0.10, ** p<0.05, *** p<0.01 
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Table A5       
Labor Force Participation Rate   
  
Substance 
Abuse Facilities 
SA Facilities 
Accepting 
Medicaid 
Facilities 
Providing 
Some MAT 
Facilities 
Providing 
MAT and 
Accepting 
Medicaid 
Facilities 
Providing Two or 
More Forms of 
MAT 
Facilities 
Providing Two 
plus forms MAT 
and Accepting 
Medicaid 
Panel A: ACS 0.00513* 0.0177*** 0.0409*** 0.0819*** 0.0105*** 0.0853*** 
 (0.0000262) (0.0000564) (0.0000620) (0.000127) (0.0000247) (0.000203) 
N 8,307 8,307 8,307 8,307 8,307 8,307 
Mean 0.66 0.66 0.66 0.66 0.66 0.66 
 
      
Panel B: BLS 0.00195 0.0230* 0.0190 0.0799*** 0.000889 0.0921*** 
and NHCS (0.0000621) (0.000133) (0.000140) (0.000255) (0.0000575) (0.000327) 
N 33,769 33,769 33,769 33,769 33,769 33,769 
Mean 0.63 0.63 0.63 0.63 0.63 0.63 
Notes: Dependent variable - labor force participation rate. Linear probability model coefficients scaled up by 100 for interpretation. 
Controls include the fraction of the county population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the 
unemployment rate and the natural log of per capita income. Treatment facilities are a count variable per county per year by type of 
facility. Models include county, year and state by year fixed effects. These estimates are weighted by county population. Standard 
errors in parenthesis are adjusted for clustering at the county level. * p<0.10, ** p<0.05, *** p<0.01 
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Table A6       
Inflation Adjusted Median and Mean Income   
  
Substance 
Abuse Facilities 
SA Facilities 
Accepting 
Medicaid 
Facilities 
Providing 
Some MAT 
Facilities 
Providing 
MAT and 
Accepting 
Medicaid 
Facilities 
Providing Two or 
More Forms of 
MAT 
Facilities 
Providing Two 
plus forms MAT 
and Accepting 
Medicaid 
Panel A: Log Median 0.0000202 0.0000219 0.000104 -0.000225 0.000162* 0.000595 
Household Income (0.0000826) (0.000166) (0.000303) (0.000362) (0.0000876) (0.000447) 
Mean 61,585 61,585 61,585 61,585 61,585 61,585 
 
      
Panel B: Log Median 0.000267** 0.000525** 0.000417 0.000754 0.000273** 0.000551 
Non-Family Income (0.000107) (0.000260) (0.000283) (0.000549) (0.000135) (0.000623) 
Mean 38,220 38,220 38,220 38,220 38,220 38,220 
 
      
Panel C: Log Mean 0.000122* 0.000214* -0.000166 -0.000346 -0.0000295 0.000174 
Household Income (0.0000646) (0.000127) (0.000238) (0.000278) (0.0000604) (0.000438) 
 82,321 82,321 82,321 82,321 82,321 82,321 
 
      
Panel D: Log Mean 0.000255*** 0.000423* 0.0000453 0.000204 -0.0000600 0.000207 
Non-Family Income (0.0000980) (0.000230) (0.000218) (0.000374) (0.000113) (0.000701) 
Mean 52,275 52,275 52,275 52,275 52,275 52,275 
N 8,343 8,343 8,343 8,343 8,343 8,343 
Notes: Dependent variable - log county level mean/median income. Controls include the fraction of the county population that are white, 
black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and the natural log of per capita income. 
Treatment facilities are a count variable per county per year by type of facility. Models include county, year and state by year fixed 
effects. These estimates are weighted by county population. Standard errors in parenthesis are adjusted for clustering at the county level. 
* p<0.10, ** p<0.05, *** p<0.01 
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Table A7       
Reverse Causality   
  
Substance 
Abuse 
Facilities 
SA Facilities 
Accepting 
Medicaid 
Facilities 
Providing 
Some MAT 
Facilities 
Providing 
MAT and 
Accepting 
Medicaid 
Facilities 
Providing Two 
or More Forms 
of MAT 
Facilities 
Providing Two 
plus forms MAT 
and Accepting 
Medicaid 
Panel A: One Year before Opening      
Opioid Death Rate per 100,000 0.0102 0.00224 0.000980 0.00136 0.00357 0.0123* 
 (0.00744) (0.00499) (0.00537) (0.00311) (0.00945) (0.00632) 
N 31,935 31,935 31,935 31,935 31,935 31,935 
 
      
Panel B: Two Years before Opening      
Opioid Death Rate per 100,000 0.00740 0.0124 0.00265 -0.00863** 0.0114 -0.00453 
 (0.00488) (0.00877) (0.00624) (0.00404) (0.0104) (0.00317) 
N 29,152 29,152 29,152 29,152 29,152 29,152 
Notes: Dependent variable - indicator variable for substance abuse facility openings. Controls include the fraction of the county 
population that are: white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and per capita income. 
Models include county FE, year FE and state by year FE. These estimates are weighted by county population. Standard errors in 
parenthesis are adjusted for clustering at the county level. * p<0.10, ** p<0.05, *** p<0.01 
131 
Table A8 
   
Testing County Population Composition Changes 
  
Substance Abuse 
Facilities 
SA Facilities 
Accepting 
Medicaid 
Facilities 
Providing 
Some MAT 
Population Share  -0.00000881 -0.0000450* -0.0000250 
Ages 16-34 (0.0000119) (0.0000261) (0.0000204)  
   
Population Share  0.00000515 0.00000676 -0.00000341 
Female (0.00000322) (0.00000537) (0.00000602)  
   
Population Share  0.00000967 0.00000669 0.000113* 
White (0.0000233) (0.0000460) (0.0000654)  
   
Population Share  -0.0000138 -0.0000357 -0.000157*** 
Black (0.0000235) (0.0000480) (0.0000577) 
N 33,197 33,197 33,197 
Notes: Dependent variable - share of county population within demographics group. 
Controls include the unemployment rate and per capita income. Models include county, 
year and state by year fixed effects. These estimates are weighted by county population. 
Standard errors in parenthesis are adjusted for clustering at the county level. * p<0.10, ** 
p<0.05, *** p<0.01 
 
 
 
 
 
 
 
 
 
 
